85. 特発性間質性肺炎 ［臨床試験数：257，薬物数：256（DrugBank：93），標的遺伝子数：76，標的パスウェイ数：182］
Searched query = "Idiopathic interstitial pneumonia", "Idiopathic pulmonary fibrosis", "Usual interstitial pneumonia", "Non specific interstitial pneumonia", "NSIP", "Organizing pneumonia", "Desquamative interstitial pneumonia", "Respiratory bronchiolitis associated interstitial lung disease", "RB ILD", "Lymphocytic interstitial pneumonia", "Acute interstitial pneumonia", "Diffuse alveolar damage"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03720483 | January 2020 | 15 July 2019 | Inhaled NAC in Treatment of IPF | Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Drug: N-acetyl cysteine then Placebo;Drug: Placebo then N-acetyl cysteine | University of Colorado, Denver | Not recruiting | 40 Years | 75 Years | All | 50 | Phase 1/Phase 2 | United States | |
| 2 | NCT03865927 | November 1, 2019 | 30 September 2019 | GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of GKT137831 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Other: Placebo Oral Tablet;Drug: GKT137831 | University of Alabama at Birmingham | Not recruiting | 40 Years | 85 Years | All | 60 | Phase 2 | United States | |
| 3 | ChiCTR1900027121 | 2019-10-28 | 4 November 2019 | The efficacy and safety of immunosuppressant in the treatment of nonspecific interstitial pneumonia (NSIP): a prospective, single-center, open, parallel-controlled trial | The efficacy and safety of immunosuppressant in the treatment of nonspecific interstitial pneumonia (NSIP): a prospective, single-center, open, parallel-controlled trial | nonspecific interstitial pneumonia (NSIP) | Group-1:Mycophenolate mofetil dispersible tablets 2 g /d; Steroid 0.75 mg/kg/d;Group-2:Tacrolimus capsule, 3mg/d, Steroid 0.75 mg/kg/d;Group-3:Cyclophosphamide 1-2mg/kg/d, Steroid 0.75 mg/kg/d;Control group:Steroid from 0.75 mg/kg/d to 15 mg/d.; | Peking Union Medical College Hospital | Recruiting | 18 | 75 | Both | Group-1:30;Group-2:30;Group-3:30;Control group:30; | Phase 4 | China | |
| 4 | JPRN-jRCTs031190119 | 28/10/2019 | 5 November 2019 | A phase II Study of CBDCA + ETP + Nintedanib for SCLC with IPF | A Phase II Study of Carboplatin and Etoposide Plus Nintedanib for Unresectable Limited/Extensive Disease Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis - TORG1835 / NEXT-SHIP | Unresectable limited or extensive disease small cell lung cancer with idiopathic pulmonary fibrosis | The patients receive carboplatin(area under the curve 5 mg/mL, intravenously, day 1), etoposide (<75 years old:100mg/m2:>=75years old:80mg/m2;intravenously,days 1-3), and nintedanib (150mg twice a day, orally). The patients receive combination chemotherapy every3 weeks for 4 cycles until disease progression or unacceptable toxicity occurs. After completion or discontinuation of carboplatin plus etoposide, the patients continue nintedanib until the discontinuation criteria are satisfied. | Takashi OGURA | Satoshi IKEDA;Thoracic Oncology Research Group | Recruiting | >= 20age old | Not applicable | Both | 33 | Phase 2 | none |
| 5 | NCT04071769 | October 1, 2019 | 9 September 2019 | Genentech MRI Study | Using Xenon MRI to Evaluate the Efficacy of Therapies for Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | Duke University | Not recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04072315 | September 9, 2019 | 30 September 2019 | Phase 2a Evaluation of PLN-74809 on avß6 Receptor Occupancy Using PET Imaging in Participants With IPF/ | A Phase 2a Evaluation of PLN-74809 on avß6 Receptor Occupancy Using PET Imaging in Participants With IPF | Idiopathic Pulmonary Fibrosis | Drug: PLN-74809;Drug: Placebo;Radiation: Knottin tracer | Pliant Therapeutics, Inc. | Stanford University | Recruiting | 40 Years | 80 Years | All | 18 | Phase 2 | United States |
| 7 | JPRN-jRCTs031190084 | 05/09/2019 | 7 October 2019 | TORG1936 / AMBITIOUS study | A phase II study of Atezolizumab for advanced / recurrent Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias - TORG1936 / AMBITIOUS study | Advanced / recurrent Non-small cell lung cancer with idiopathic interstitial pneumonia | Atezolizumab 1200mg, every 3 weeks | Terufumi KATO | Satoshi IKEDA | Recruiting | >= 20age old | Not applicable | Both | 38 | Phase 2 | none |
| 8 | NCT03800017 | September 1, 2019 | 15 July 2019 | Skeletal Muscle Function in Interstitial Lung Disease | Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease | Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis;Scleroderma;Nonspecific Interstitial Pneumonia | Biological: Hyperoxia | University of British Columbia | Not recruiting | 40 Years | 80 Years | All | 40 | N/A | ||
| 9 | NCT03939520 | September 2019 | 20 May 2019 | Management of Progressive Disease in Idiopathic Pulmonary Fibrosis | Pragmatic Management of Progressive Disease in Idiopathic Pulmonary Fibrosis: a Randomized Trial | Progressive Idiopathic Pulmonary Fibrosis | Drug: pirfenidone and nintedanib;Drug: pirfenidone or nintedanib | Hospices Civils de Lyon | Not recruiting | 50 Years | 80 Years | All | 210 | Phase 4 | France | |
| 10 | NCT04030026 | August 8, 2019 | 29 July 2019 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough | Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough | Nalbuphine;Idiopathic Pulmonary Fibrosis;Cough | Drug: Nalbuphine ER;Drug: Placebo oral tablet | Trevi Therapeutics | Parexel | Not recruiting | 18 Years | 80 Years | All | 56 | Phase 2 | United Kingdom |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03562416 | July 5, 2019 | 22 July 2019 | Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects | Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled Trial | Idiopathic Pulmonary Fibrosis;Lung Transplant; Complications | Drug: Nintedanib;Drug: Placebo Oral Tablet | Temple University | Boehringer Ingelheim | Recruiting | 35 Years | 70 Years | All | 20 | Phase 2 | United States |
| 12 | NCT03955146 | June 27, 2019 | 28 October 2019 | Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Pamrevlumab;Drug: Placebo | FibroGen | Recruiting | 40 Years | 85 Years | All | 565 | Phase 3 | United States | |
| 13 | NCT03981094 | May 6, 2019 | 26 August 2019 | A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants | An Open Label Study to Assess the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 Following a Single Oral Dose Administration in Healthy Participants | Idiopathic Pulmonary Fibrosis (IPF) | Drug: BMS-986278;Drug: Pirfenidone | Bristol-Myers Squibb | Recruiting | 21 Years | 65 Years | All | 22 | Phase 1 | United States | |
| 14 | NCT03949530 | April 16, 2019 | 27 May 2019 | A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis | IDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Healthy Volunteers;Idiopathic Pulmonary Fibrosis | Drug: IDL-2965 Oral Capsule;Drug: Placebos | Indalo Therapeutics, Inc. | Recruiting | 18 Years | 60 Years | All | 120 | Phase 1 | United Kingdom | |
| 15 | NCT03864328 | March 29, 2019 | 11 November 2019 | A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study With Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial | Persistent Cough in IPF;Chronic Cough;IPF | Drug: RVT-1601;Drug: Placebo | Respivant Sciences GmbH | Respivant Sciences Inc. | Recruiting | 40 Years | 89 Years | All | 180 | Phase 2 | United States;Australia;Belgium;Canada;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03710824 | February 28, 2019 | 28 October 2019 | Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib | Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib | Idiopathic Pulmonary Fibrosis | Drug: Nintedanib | Boehringer Ingelheim | Recruiting | 40 Years | N/A | All | 120 | Phase 2 | Greece | |
| 17 | NCT03650075 | February 25, 2019 | 15 July 2019 | To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers | A Phase I Study to Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers | Idiopathic Pulmonary Fibrosis (IPF) | Drug: MG-S-2525 | Metagone Biotech Inc. | Recruiting | 20 Years | N/A | All | 72 | Phase 1 | Taiwan | |
| 18 | NCT03832946 | February 19, 2019 | 4 March 2019 | A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | GALACTIC-1 A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered Via Dry Powder Inhaler Over 52 Weeks | Idiopathic Pulmonary Fibrosis (IPF) | Drug: TD139;Drug: Placebo | Galecto Biotech AB | Syneos Health | Recruiting | 40 Years | N/A | All | 450 | Phase 2 | United States |
| 19 | NCT03830125 | February 13, 2019 | 4 November 2019 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects | A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects | Idiopathic Pulmonary Fibrosis | Drug: BBT-877, Single dose;Drug: Placebo group;Drug: BBT-877, Multiple doses | Bridge Biotherapeutics, Inc. | KCRN Research, LLC | Recruiting | 19 Years | 55 Years | All | 64 | Phase 1 | United States |
| 20 | EUCTR2018-001406-29-FR | 28/01/2019 | 28 February 2019 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0 Level: SOC Classification code 10038738 Term: Respiratory, thoracic and mediastinal disorders System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not applicable Current Sponsor code: G451990 Other descriptive name: GLPG1690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: GLPG1690 Product Code: G451990 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not applicable Current Sponsor code: G451990 Other descriptive name: GLPG1690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Galapagos NV | Authorised | Female: yes Male: yes | 750 | Phase 3 | United States;Israel;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;South Africa;Germany;Netherlands;New Zealand;Korea, Republic of | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03958071 | December 19, 2018 | 11 June 2019 | A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking | Characteristics of IPF Patients Initiating Nintedanib, Pirfenidone or no Antifibrotic Treatment in the US | Idiopathic Pulmonary Fibrosis | Drug: Nintedanib;Drug: Pirfenidone;Other: Untreated Cohort | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 13264 | N/A | United States | |
| 22 | EUCTR2018-001405-87-ES | 12/12/2018 | 28 February 2019 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0 Level: SOC Classification code 10038738 Term: Respiratory, thoracic and mediastinal disorders System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not applicable Current Sponsor code: G451990 Other descriptive name: GLPG1690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: GLPG1690 Product Code: G451990 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not applicable Current Sponsor code: G451990 Other descriptive name: GLPG1690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Galapagos NV | Authorised | Female: yes Male: yes | 750 | Phase 3 | United States;Taiwan;Greece;Finland;Spain;Turkey;Chile;United Kingdom;Czech Republic;Belgium;Peru;Australia;Denmark;Germany | |||
| 23 | NCT03711162 | November 28, 2018 | 11 November 2019 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care | A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: GLPG1690;Drug: Placebo | Galapagos NV | Recruiting | 40 Years | N/A | All | 750 | Phase 3 | United States;Australia;Belgium;Chile;Czechia;Denmark;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom | |
| 24 | NCT03727802 | November 28, 2018 | 11 November 2019 | Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis | TRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: TRK-250;Drug: Placebo | Toray Industries, Inc | Recruiting | 40 Years | 80 Years | All | 34 | Phase 1 | United States | |
| 25 | NCT03717012 | November 15, 2018 | 28 October 2019 | Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL | Idiopathic Pulmonary Fibrosis | Drug: Nintedanib;Other: Pulmonary rehabilitation program | Boehringer Ingelheim | Recruiting | 40 Years | N/A | All | 290 | Phase 4 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | EUCTR2018-002632-24-FR | 13/11/2018 | 30 April 2019 | to evaluate a triple therapy: plasma exchange, rituximab, intravenous immunoglobulin (IVIg) and corticosteroid administration compared to standard corticosteroid therapy in patients for severe acute exacerbation of idiopathic pulmonary | Therapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial - EXCHANGE-IFP | severe acute exacerbation of idiopathic pulmonary fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: RIXATHON 500 mg Pharmaceutical Form: Concentrate for solution for infusion Trade Name: PRIVIGEN 100mg/ml Pharmaceutical Form: Solution for infusion | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | 40 | Phase 3 | France | |||
| 27 | NCT03733444 | November 5, 2018 | 22 October 2019 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care | A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: GLPG1690;Drug: Placebo | Galapagos NV | Recruiting | 40 Years | N/A | All | 750 | Phase 3 | United States;Argentina;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa | |
| 28 | NCT03725852 | September 27, 2018 | 14 October 2019 | A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: GLPG1205;Drug: Placebo | Galapagos NV | Recruiting | 40 Years | N/A | All | 60 | Phase 2 | Bulgaria;Croatia;Finland;France;Oman;Slovakia;Sweden;Ukraine | |
| 29 | NCT03573505 | September 24, 2018 | 30 September 2019 | An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: BG00011;Drug: Placebo | Biogen | Not recruiting | 40 Years | N/A | All | 109 | Phase 2 | United States;Argentina;Australia;Belgium;Chile;Czechia;Denmark;France;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom | |
| 30 | EUCTR2017-003158-18-GR | 21/09/2018 | 15 October 2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Not yet assigned Current Sponsor code: BG00011 Other descriptive name: BG00011 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 56- Pharmaceutical form of the placebo: Injection Route of administration of the placebo: Subcutaneous use | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT03286556 | September 4, 2018 | 30 September 2019 | Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis | Study of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF) | Idiopathic Pulmonary Fibrosis, Acute Fatal Form | Drug: Autoantibody Reductive Therapy;Drug: Treatment as Usual (TAU) | University of Alabama at Birmingham | National Heart, Lung, and Blood Institute (NHLBI);Brigham and Women's Hospital;Temple University;University of Pittsburgh | Recruiting | 40 Years | 85 Years | All | 51 | Phase 2 | United States |
| 32 | NCT03535545 | August 1, 2018 | 30 September 2019 | Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients | Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer Patients Undergoing Radiation Therapy Prior to the Resection of Locally Advanced Tumors, and Idiopathic Pulmonary Fibrosis Patients | Pulmonary Fibrosis;Lung Cancer | Drug: [68Ga]CBP8;Diagnostic Test: PET Imaging | Massachusetts General Hospital | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 18 Years | 80 Years | All | 25 | Phase 1 | United States |
| 33 | EUCTR2017-003158-18-ES | 27/07/2018 | 20 August 2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Not yet assigned Current Sponsor code: BG00011 Other descriptive name: BG00011 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 56- Pharmaceutical form of the placebo: Injection Route of administration of the placebo: Subcutaneous use | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | |||
| 34 | NCT03619616 | July 16, 2018 | 4 November 2019 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults | A Phase 1 Randomized,Double-Blind,Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1603 in Chinese Healthy Subjects | Idiopathic Pulmonary Fibrosis(IPF);Solid Tumor | Drug: ZSP1603 7.5 mg;Drug: ZSP1603 12.5 mg;Drug: Placebo 12.5mg;Drug: ZSP1603 25 mg;Drug: Placebo 25mg;Drug: ZSP1603 50 mg;Drug: Placebo 50mg | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Not recruiting | 18 Years | 50 Years | All | 40 | Phase 1 | China | |
| 35 | NCT03928847 | July 1, 2018 | 6 May 2019 | Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. | Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. | Idiopathic Pulmonary Fibrosis | Drug: Epigallocatechin-3-gallate (EGCG) | University of California, San Francisco | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 40 Years | 70 Years | All | 35 | Phase 1/Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | EUCTR2017-004302-18-SK | 18/06/2018 | 28 February 2019 | A clinical study to test how effective and safe GLPG1205 is for patients with Idiopathic Pulmonary Fibrosis (IPF) | A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1205 Product Code: G321605 Pharmaceutical Form: Capsule, hard INN or Proposed INN: NA CAS Number: 1445847-37-9 Current Sponsor code: G321605 Other descriptive name: GLPG1205 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Galapagos NV | Authorised | Female: yes Male: yes | 60 | Phase 2 | France;Egypt;Slovakia;Finland;Oman;Ukraine;Romania;Croatia;Bulgaria;Sweden | |||
| 37 | NCT03538301 | June 18, 2018 | 4 November 2019 | A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: ND-L02-s0201;Other: Other: Placebo | Nitto Denko Corporation | Recruiting | 40 Years | 80 Years | All | 120 | Phase 2 | United States;Germany;United Kingdom | |
| 38 | EUCTR2017-002667-17-FR | 06/06/2018 | 28 February 2019 | Study of pharmacodynamics, pharmacokinetics, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis | A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: VAY736 Pharmaceutical Form: Powder for solution for injection/infusion INN or Proposed INN: not established Other descriptive name: VAY736 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Subcutaneous use | Novartis Pharma AG | Authorised | Female: yes Male: yes | 84 | Phase 2 | United States;France;Canada;Ireland;Germany;Italy;United Kingdom | |||
| 39 | NCT03688334 | June 1, 2018 | 9 October 2018 | Acute Effects of Oxygen Supplementation Among IPF Patients | Acute Effects of Oxygen Supplementation During Exercise Among Patients With Idiopathic Pulmonary Fibrosis Without Resting Hypoxemia | Idiopathic Pulmonary Fibrosis | Drug: Oxygen 40 %;Drug: Medical air (sham O2) | George Papanicolaou Hospital | Recruiting | 18 Years | 80 Years | All | 15 | N/A | Greece | |
| 40 | EUCTR2016-003827-45-GR | 29/05/2018 | 5 June 2018 | AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE | AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE - MADIET | Idiopathic Pulmonary Fibrosis MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ESBRIET Product Name: ESBRIET Pharmaceutical Form: Capsule, hard INN or Proposed INN: PIRFENIDONE CAS Number: 53179-13-8 Current Sponsor code: ESBRIET Other descriptive name: ESBRIET Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 801- Trade Name: ESBRIET Product Name: ESBRIET Pharmaceutical Form: Capsule, hard INN or Proposed INN: PIRFENIDONE CAS Number: 53179-13-8 Current Sponsor code: ESBRIET Other descriptive name: ESBRIET Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1602- Trade Name: ESBRIET Product Name: ESBRIET Pharmaceutical Form: Capsule, hard INN or Proposed INN: PIRFENIDONE CAS Number: 53179-13-8 Current Sponsor code: ESBRIET Other descriptive name: ESBRIET Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2403- | CIBERES - Instituto Carlos III | Institut d'Investigació Biomédica de Bellvitge (IDIBELL) | Authorised | Female: yes Male: yes | 90 | Phase 4 | Greece;Spain | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT03502902 | May 22, 2018 | 17 September 2018 | The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects | HEC68498 - A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female Subjects | Idiopathic Pulmonary Fibrosis | Drug: HEC 68498;Drug: Placebo | Sunshine Lake Pharma Co., Ltd. | Covance | Recruiting | 18 Years | 60 Years | All | 72 | Phase 1 | United States |
| 42 | NCT03500731 | April 19, 2018 | 15 April 2019 | Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure | Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure | Idiopathic Pulmonary Fibrosis;Emphysema or COPD | Biological: CD3/CD19 negative hematopoietic stem cells;Drug: Rituximab;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Thiotepa;Drug: G-CSF;Drug: Hydroxyurea | Paul Szabolcs | Recruiting | 18 Years | 60 Years | All | 8 | Phase 1/Phase 2 | United States | |
| 43 | NCT03422068 | March 16, 2018 | 4 November 2019 | This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated. | Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic Therapy. | Idiopathic Pulmonary Fibrosis | Drug: BI 1015550;Drug: Placebo | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 15 | Phase 1 | Belgium;Denmark;Finland;Germany;Italy;Netherlands;Spain;United Kingdom;France | |
| 44 | NCT02871401 | January 3, 2018 | 18 March 2019 | A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF) | A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Valganciclovir;Drug: Placebo | Vanderbilt University Medical Center | Genentech, Inc. | Not recruiting | 21 Years | 80 Years | All | 30 | Phase 1 | United States |
| 45 | NCT03287414 | December 20, 2017 | 9 September 2019 | Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis | A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: VAY736;Drug: Placebo | Novartis Pharmaceuticals | Recruiting | 40 Years | 80 Years | All | 84 | Phase 2 | United States;Canada;France;Germany;Ireland;Italy;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT03183570 | November 8, 2017 | 15 July 2019 | Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis Using PET/CT | Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis With [18F]FP-R01-MG-F2 PET/CT | Idiopathic Pulmonary Fibrosis | Drug: [18F]FP-R01-MG-F2 | Stanford University | Pliant Therapeutics, Inc. | Recruiting | 60 Years | N/A | All | 10 | Early Phase 1 | United States |
| 47 | NCT03281200 | October 24, 2017 | 18 June 2018 | Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain | A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain. | Idiopathic Pulmonary Fibrosis | Drug: L01XE31 - Nintedanib;Drug: L01XE - Protein kinase inhibitors;Drug: L01X - Other antineoplastic agents;Drug: L01 - Antineoplastic agents;Drug: L - Antineoplastic and immunomodulating agents | Boehringer Ingelheim | Not recruiting | 18 Years | N/A | All | 173 | Phase 1 | Spain | |
| 48 | NCT03208933 | October 23, 2017 | 22 October 2019 | Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). | Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone | Hoffmann-La Roche | Not recruiting | 40 Years | 80 Years | All | 59 | Phase 3 | Russian Federation | |
| 49 | JPRN-UMIN000029411 | 2017/10/15 | 2 April 2019 | Phase III study of perioperative pirfenidone therapy in patients with non-small-cell lung cancer combined with idiopathic pulmonary fibrosis (IPF) for confirming the effect for prevention of postoperative acute exacerbation | non-small-cell lung cancer combined with idiopathic pulmonary fibrosis | Oral pirfenidone (600mg) is administrated for 14days after registration, and oral pirfenidone (1200mg) for more 14days before surgery. It's recommended continuing oral pirfenidone as long as possible even after surgery. Acute exacerbation prophylaxis is performed (not specified. but decided in each facility) | North East Japan Study Group | Recruiting | 20years-old | Not applicable | Male and Female | 230 | Phase 3 | Japan | ||
| 50 | JPRN-UMIN000026376 | 2017/09/01 | 10 September 2019 | Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis | Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in IPF | Idiopathic pulmonary fibrosis(IPF) | Short-term induction pulmonary rehabilitation (2/1w for the first 12w) + Maintenance pulmonary rehabilitation and outpatient visit (1/4w) Total 52w. / No intervention Nintedanib / both group | Central Japan Lung Study Grou | Recruiting | 40years-old | 80years-old | Male and Female | 84 | Phase 4 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT03142191 | July 26, 2017 | 22 October 2019 | A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis | A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Fibrosis;Idiopathic Interstitial Pneumonias;Pathologic Processes;Lung Diseases, Interstitial;Lung Diseases;Respiratory Tract Diseases | Drug: CC-90001;Other: Placebo | Celgene | Recruiting | 40 Years | N/A | All | 210 | Phase 2 | United States;Australia;Brazil;Canada;Colombia;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United Kingdom;China | |
| 52 | NCT03069989 | June 13, 2017 | 21 January 2019 | Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging | A Study of Single Doses to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of Nebulised GSK3008348 in Idiopathic Pulmonary Fibrosis Patients, Using Positron Emission Tomography (PET) Imaging | Idiopathic Pulmonary Fibrosis | Drug: [18F]-FBA-A20FMDV2;Drug: Placebo;Drug: GSK3008348 | GlaxoSmithKline | Not recruiting | 50 Years | N/A | All | 8 | Phase 1 | United Kingdom | |
| 53 | JPRN-jRCTs071180049 | 23/05/2017 | 10 September 2019 | Japanese Intergroup Study of Nintedanib for NSCLC with IPF | A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - J-SONIC | Advanced Non-small cell lung cancer with idiopathic pulmonary fibrosis | carboplatin + nab-paclitaxel carboplatin + nab-paclitaxel + nintedanib | Isamu Okamoto | Kohei Otsubo | Recruiting | >= 20age old | Not applicable | Both | 240 | Phase 3 | none |
| 54 | NCT03092102 | May 20, 2017 | 17 September 2018 | The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects | A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects | Idiopathic Pulmonary Fibrosis | Drug: HEC585 | Sunshine Lake Pharma Co., Ltd. | Recruiting | 18 Years | 60 Years | All | 84 | Phase 1 | United States | |
| 55 | JPRN-UMIN000026799 | 2017/05/12 | 7 October 2019 | A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis | A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - Japanese Intergroup Study of Nintedanib for NSCLC with IPF (J-SONIC) | Non-small-cell lung cancer with idiopathic pulmonary fibrosis | A: 4 cycles of Carboplatin (AUC 6, day 1) plus nab-Paclitaxel (100 mg/m2, day 1, 8, 15) repeated every 3 weeks B: 4 cycles of Carboplatin (AUC 6, day 1) plus nab-Paclitaxel (100 mg/m2, day 1, 8, 15) in combination with nintedanib (150 mg B.I.D, daily) repeated every 3 weeks followed by single-agent administration of nintedanib (150 mg B.I.D, daily) | Research Institute for Diseases of the Chest, Kyushu University | Recruiting | 20years-old | Not applicable | Male and Female | 240 | Phase 3 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | EUCTR2016-003473-17-GR | 05/05/2017 | 19 November 2018 | Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary Fibrosis | A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis | IDIOPATHIC PULMONARY FIBROSIS MedDRA version: 20.0 Level: LLT Classification code 10067761 Term: Exacerbation of idiopathic pulmonary fibrosis System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: CC-90001 Pharmaceutical Form: Film-coated tablet CAS Number: 1403859-14-2 Current Sponsor code: CC-90001 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Celgene Corporation | Authorised | Female: yes Male: yes | 135 | Phase 2 | United States;Taiwan;Greece;Turkey;Russian Federation;Colombia;United Kingdom;France;Canada;Brazil;Romania;Australia;Germany | |||
| 57 | NCT03115619 | April 18, 2017 | 22 October 2019 | Quality of Life Study in Participants With IPF Under Pirfenidone Treatment | A Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon Study | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone | Hoffmann-La Roche | Not recruiting | 18 Years | N/A | All | 102 | Phase 3 | Greece | |
| 58 | NCT02759120 | March 22, 2017 | 30 September 2019 | CleanUP IPF for the Pulmonary Trials Cooperative | Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Antimicrobial therapy: Co-trimoxazole or Doxycycline;Other: No Intervention: Standard of Care | Weill Medical College of Cornell University | Duke Clinical Research Institute;University of Chicago;University of Washington;University of Pittsburgh;National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 40 Years | N/A | All | 509 | Phase 3 | United States |
| 59 | NCT02951429 | January 13, 2017 | 14 October 2019 | Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension | A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Group 3 Pulmonary Hypertension | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone;Drug: Placebo;Drug: Sildenafil | Hoffmann-La Roche | Not recruiting | 40 Years | 80 Years | All | 177 | Phase 2 | Belgium;Canada;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;Czech Republic;United Arab Emirates | |
| 60 | NCT03018756 | January 2017 | 1 October 2018 | Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea | Use of Nebulized Fentanyl in Patients With Mild-to-Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea | Idiopathic Pulmonary Fibrosis | Drug: Fentanyl Citrate;Drug: Placebo | Queen's University | Boehringer Ingelheim (Canada) LTD | Recruiting | 40 Years | N/A | All | 20 | Phase 3 | Canada |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT02874989 | December 16, 2016 | 15 July 2019 | Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial | Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Drug: Dasatinib + Quercetin;Drug: Placebo | Wake Forest University Health Sciences | Mayo Clinic;The University of Texas Health Science Center at San Antonio | Not recruiting | 50 Years | N/A | All | 26 | Phase 1 | United States |
| 62 | NCT02989168 | November 2016 | 16 December 2017 | Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest | A Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR) | Idiopathic Pulmonary Fibrosis | Drug: GBT440 | Global Blood Therapeutics | Not recruiting | 45 Years | 85 Years | All | 14 | Phase 2 | United States;United Kingdom | |
| 63 | NCT03050255 | November 2016 | 18 December 2018 | Short-term Effects of Supplemental Oxygen in Patients With IPF | Short-term Effects of Supplemental Oxygen During Walking in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Other: Oxygen (4Liter/min);Other: Oxygen (2Liter/min);Other: Medical air | Klinikum Berchtesgadener Land der Schön-Kliniken | Linde AG | Not recruiting | N/A | N/A | All | 53 | N/A | Germany |
| 64 | EUCTR2015-005131-40-ES | 20/10/2016 | 31 October 2016 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Pulmonary Hypertension due to the lung disease. | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND INTERMEDIATE OR HIGH PROBABILITY OF GROUP 3 PULMONARY HYPERTENSION. | Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 Pharmaceutical Form: Capsule, hard INN or Proposed INN: PIRFENIDONE CAS Number: 53179-13-8 Current Sponsor code: RO0220912 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 267- Trade Name: Sildenafil Product Name: Sildenafil Product Code: RO0280296 Pharmaceutical Form: Capsule, hard INN or Proposed INN: SILDENAFIL CAS Number: 139755-83-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 176 | Phase 2 | United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Czech Republic;Hungary;Canada;Belgium;South Africa;Germany;Netherlands | |||
| 65 | NCT02885961 | August 2016 | 5 September 2016 | The Coagulation Cascade in Idiopathic Pulmonary Fibrosis | Investigating the Role of the Coagulation Cascade in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;IPF;Interstitial Lung Disease | Drug: Dabigatran;Radiation: FDG PET scan | University College, London | Not recruiting | 40 Years | 80 Years | Both | 12 | N/A | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | EUCTR2015-002619-14-DE | 21/07/2016 | 5 June 2018 | Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairment | INSTAGE(TM): A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment - INSTAGE(TM) | patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib CAS Number: 656247-17-5 Other descriptive name: NINTEDANIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib CAS Number: 656247-17-5 Other descriptive name: NINTEDANIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Trade Name: Revatio Product Name: Revatio 20 mg Product Code: sildenafil Pharmaceutical Form: Capsule, hard INN or Proposed INN: SILDENAFIL CAS Number: 139755-83-2 Other descriptive name: sildenafil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Boehringer Ingelheim Pharma GmbH & Co. KG | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | United States;Spain;United Kingdom;Italy;India;France;Mexico;Canada;Belgium;Australia;Germany;China;Japan;Korea, Republic of | |||
| 67 | NCT02802345 | June 30, 2016 | 3 December 2018 | Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment | INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment | Idiopathic Pulmonary Fibrosis | Drug: Nintedanib;Drug: Placebo;Drug: Sildenafil | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 274 | Phase 3 | United States;Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom | |
| 68 | EUCTR2015-003148-38-ES | 13/06/2016 | 18 June 2018 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 18.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib CAS Number: 656247-17-5 Other descriptive name: NINTEDANIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib CAS Number: 656247-17-5 Other descriptive name: NINTEDANIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Boehringer Ingelheim España, S.A. | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of | |||
| 69 | NCT02788474 | June 9, 2016 | 2 July 2018 | Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment | A 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Limited Forced Vital Capacity (FVC) Impairment. | Idiopathic Pulmonary Fibrosis | Drug: nintedanib;Drug: placebo | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 347 | Phase 4 | United States;Australia;Belgium;Czechia;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;Czech Republic | |
| 70 | EUCTR2015-003148-38-GB | 06/06/2016 | 28 February 2019 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib CAS Number: 656247-17-5 Other descriptive name: NINTEDANIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib CAS Number: 656247-17-5 Other descriptive name: NINTEDANIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Boehringer Ingelheim Limited | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT02688647 | June 2016 | 26 August 2019 | A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis | A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: KD025;Drug: Standard of Care | Kadmon Corporation, LLC | Not recruiting | 18 Years | N/A | All | 76 | Phase 2 | United States | |
| 72 | NCT02846324 | June 2016 | 16 December 2017 | Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF | A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: GBT440;Drug: Placebo | Global Blood Therapeutics | Not recruiting | 45 Years | 80 Years | All | 39 | Phase 2 | United States | |
| 73 | JPRN-JapicCTI-163326 | 01/5/2016 | 16 July 2019 | Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis | Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis | Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) | Intervention name : ART-123 INN of the intervention : thrombomodulin alfa Dosage And administration of the intervention : 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy Control intervention name : Placebo Dosage And administration of the control intervention : Placebo by intravenous drip infusion in addition to standard of care steroid therapy | ASAHI KASEI PHARMA CORPORATION | Recruiting | 40 | 85 | BOTH | Phase 3 | |||
| 74 | NCT02739165 | May 2016 | 28 January 2019 | Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123 | Idiopathic Pulmonary Fibrosis | Drug: ART-123;Drug: Placebo | Asahi Kasei Pharma Corporation | Not recruiting | 40 Years | 85 Years | All | 74 | Phase 3 | Japan | |
| 75 | NCT02606877 | April 19, 2016 | 8 January 2018 | A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination | Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study) | Idiopathic Pulmonary Fibrosis | Drug: nintedanib;Drug: pirfenidone | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 37 | Phase 4 | United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | JPRN-UMIN000021591 | 2016/04/04 | 7 October 2019 | The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia | The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia - The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia | Advanced non-small cell lung cancer with idiopathic interstitial pneumonia | carboplatin AUC6 D1 paclitaxel 200mg/m D1 tryweekly 4cycle nintedanib 150mg twice daily | Hirosaki University Graduate School of Medicine | Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan | |
| 77 | NCT02745184 | April 2016 | 24 September 2018 | Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: Lung stem cells | Shanghai East Hospital | Regend Therapeutics | Recruiting | 40 Years | 75 Years | All | 20 | Phase 1/Phase 2 | China | |
| 78 | EUCTR2015-004157-41-GB | 21/03/2016 | 30 April 2019 | Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 18.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 Pharmaceutical Form: Capsule Current Sponsor code: G451990 Other descriptive name: GLPG1690 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Galapagos NV | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | Ukraine;United Kingdom | |||
| 79 | NCT02503657 | March 2016 | 11 June 2019 | Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis;IPF | Drug: tipelukast;Drug: Placebo | MediciNova | Recruiting | 21 Years | 80 Years | All | 15 | Phase 2 | United States | |
| 80 | EUCTR2015-003280-11-DE | 25/02/2016 | 3 July 2017 | A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary Fibrosis | AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 Pharmaceutical Form: Capsule, hard INN or Proposed INN: PIRFENIDONE CAS Number: 53179-13-8 Current Sponsor code: RO0220912 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 267- Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 Pharmaceutical Form: Capsule, soft INN or Proposed INN: NINTEDANIB CAS Number: 656247-17-5 Current Sponsor code: 534-1508 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 Pharmaceutical Form: Capsule, soft INN or Proposed INN: NINTEDANIB CAS Number: 656247-17-5 Current Sponsor code: 534-1508 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | F. Hoffmann-La Roche Ltd | Not Recruiting | Female: yes Male: yes | 80 | Phase 4 | France;United States;Canada;Spain;Denmark;Netherlands;Germany;Italy | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | EUCTR2014-005658-20-BG | 23/02/2016 | 30 April 2018 | FG-3019 treatment in Idiopathic Pulmonary Fibrosis (IPF) patients. | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 19.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 19.1 Level: SOC Classification code 10038738 Term: Respiratory, thoracic and mediastinal disorders System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 19.1 Level: HLT Classification code 10033979 Term: Parenchymal lung disorders NEC System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: FG-3019 10mg/mL in 10 mL vials Product Code: FG-3019 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Pamrevlumab CAS Number: 946415-13-0 Current Sponsor code: FG-3019 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | FibroGen, Inc. | Not Recruiting | Female: yes Male: yes | 136 | Phase 2 | United States;Canada;Australia;South Africa;Bulgaria;New Zealand;India | |||
| 82 | JPRN-UMIN000020722 | 2016/01/26 | 2 April 2019 | Prospective study of efficiency of fibrosis score in computed tomography as predictor after treatment with Nintedanib for idiopathic pulmonary fibrosis | idiopathic pulmonary fibrosis | administration of 150mg of nintedanib twice daily | Kanagawa Cardiovascular and Respiratory Center | Recruiting | 40years-old | Not applicable | Male and Female | 30 | Not applicable | Japan | ||
| 83 | JPRN-UMIN000020682 | 2016/01/22 | 2 April 2019 | The comparison of the efficacy and safety of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis | pirfenidone 12 months 200-600mg t.i.d or b.i.d nintedanib 12 months 100-150mg b.i.d | National Hospital Organization Ibarakihigashi National Hospital The center of Chest Diseases and Severe Motor&Intellectual Disabilities | Not Recruiting | 20years-old | Not applicable | Male and Female | 60 | Not applicable | Japan | ||
| 84 | NCT02648048 | January 15, 2016 | 16 December 2017 | A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis | A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone;Drug: Vismodegib | Hoffmann-La Roche | Not recruiting | 40 Years | 80 Years | All | 21 | Phase 1 | United States;Germany | |
| 85 | NCT02612051 | December 4, 2015 | 16 December 2017 | First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients | A FTIH Study With GSK3008348 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: GSK3008348 Nebuliser solution;Drug: Placebo Nebuliser solution;Radiation: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion | GlaxoSmithKline | Not recruiting | 18 Years | N/A | All | 40 | Phase 1 | United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | EUCTR2014-000861-32-DE | 01/12/2015 | 23 July 2018 | Standard-armed controlled study to assess the impact of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) | Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) A randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial - RELIEF | 1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosis MedDRA version: 20.0 Level: LLT Classification code 10022612 Term: Interstitial lung fibrosis System Organ Class: 100000004855 MedDRA version: 20.0 Level: LLT Classification code 10035754 Term: Pneumonitis hypersensitivity System Organ Class: 100000004855 MedDRA version: 20.0 Level: LLT Classification code 10025088 Term: Lung fibrosis System Organ Class: 100000004855 MedDRA version: 20.0 Level: LLT Classification code 10022617 Term: Interstitial pneumonia System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet® (Pirfenidon) Product Code: PZN 8881655(RochePharma AG) Pharmaceutical Form: Capsule, hard INN or Proposed INN: PIRFENIDONE CAS Number: 53179-13-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 267- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Justus Liebig Universität Giessen | Not Recruiting | Female: yes Male: yes | 374 | Phase 2 | Germany | |||
| 87 | NCT02460588 | December 2015 | 18 January 2018 | Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial | Idiopathic Pulmonary Fibrosis | Drug: Cyclophosphamide;Drug: Placebo;Drug: Corticosteroid (prednisolone) | Assistance Publique - Hôpitaux de Paris | Recruiting | 18 Years | N/A | All | 120 | Phase 3 | France | |
| 88 | NCT02551068 | December 2015 | 3 June 2019 | High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib | High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study | Idiopathic Pulmonary Fibrosis | Other: 60% Oxygen;Other: Standard of Care | University of British Columbia | Boehringer Ingelheim | Recruiting | 19 Years | N/A | All | 88 | N/A | Canada |
| 89 | JPRN-UMIN000019436 | 2015/10/16 | 2 April 2019 | Randomized Phase 2 study of Nintedanib and Pirfenidone versus Nintedanib following a clinically meaningful decline in forced vital capacity in patients with idiopathic pulmonary fibrosis administering pirfenidone | idiopathic pulmonary fibrosis | Nintedanib+pirfenidone group; Nintedanib 150mg twice daily Pirfenidone 600-1800mg/day Nintedanib group; Nintedanib 150mg twice daily | Kanagawa Cardiovascular and Respiratory Center | Not Recruiting | 40years-old | Not applicable | Male and Female | 60 | Phase 2 | Japan | ||
| 90 | NCT01462006 | October 2015 | 3 December 2018 | Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF) | Double-blind Placebo-controlled Pilot Study of Sirolimus in IPF | Idiopathic Pulmonary Fibrosis;Diffuse Parenchymal Lung Disease;Interstitial Lung Disease | Drug: sirolimus;Other: Placebo | University of Virginia | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 21 Years | 85 Years | All | 32 | N/A | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | NCT02607722 | August 31, 2015 | 22 October 2019 | All-Case Surveillance of Ofev in Patients With IPF in Japan | The Special Drug Use-results Survey (All-Case Surveillance) of Ofev® Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan | Idiopathic Pulmonary Fibrosis | Drug: Nintedanib | Boehringer Ingelheim | Not recruiting | N/A | N/A | All | 5674 | N/A | Japan | |
| 92 | EUCTR2015-000640-42-FR | 26/08/2015 | 7 September 2015 | Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPF | A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) - Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPF | Idiopathic Pulmonary Fibrosis MedDRA version: 18.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib CAS Number: 656247-17-5 Other descriptive name: NINTEDANIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib CAS Number: 656247-17-5 Other descriptive name: NINTEDANIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Trade Name: Esbriet Product Name: pirfenidone Product Code: pirfenidone Pharmaceutical Form: Capsule, hard INN or Proposed INN: PIRFENIDONE CAS Number: 53179-13-8 Current Sponsor code: PIRFENIDONE Other descriptive name: PIRFENIDONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 267- | Boehringer Ingelheim France | Authorised | Female: yes Male: yes | 135 | United States;France;Canada;Netherlands;Germany;Italy | ||||
| 93 | NCT02502097 | August 20, 2015 | 16 December 2017 | A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) | A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough | Idiopathic Pulmonary Fibrosis;Cough | Drug: Gefapixant first, then Placebo;Other: Placebo first, then Gefapixant | Afferent Pharmaceuticals, Inc. | Not recruiting | 40 Years | N/A | All | 51 | Phase 2 | United States | |
| 94 | NCT02477709 | July 20, 2015 | 1 July 2019 | A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | A Study to Assess the Tolerability of a Single Dose of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Gefapixant | Afferent Pharmaceuticals, Inc. | Not recruiting | 40 Years | N/A | All | 6 | Phase 2 | United States | |
| 95 | NCT01841307 | July 2015 | 25 February 2019 | Cromolyn Detection of Silent Aspiration | Development and Validation of Test for Gastro-esophageal Reflux and Aspiration | Gastroesophageal Reflux;Respiratory Aspiration;Idiopathic Pulmonary Fibrosis;Lung Transplantation | Drug: Cromolyn Sodium | University of California, San Francisco | Aradign Corportation;National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | 70 Years | All | 16 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | NCT02538536 | July 2015 | 29 April 2019 | A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) | Drug: PBI4050 | ProMetic BioSciences Inc. | Not recruiting | 40 Years | N/A | All | 41 | Phase 2 | Canada | |
| 97 | EUCTR2014-004782-24-NL | 06/05/2015 | 10 July 2015 | A study to test intravenous PRM-151 for safety and to see how PRM-151 acts in the body and blood of people with idiopathic pulmonary fibrosis (IPF) - a disorder where lung tissue becomes damaged and scarred making it difficult to breathe. | A Pilot Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 17.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | Product Code: PRM-151 Pharmaceutical Form: Solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Promedior inc | Authorised | Female: yes Male: yes | 60 | Netherlands | ||||
| 98 | NCT02345070 | May 1, 2015 | 25 June 2018 | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study | Idiopathic Pulmonary Fibrosis | Drug: SAR156597;Drug: placebo | Sanofi | Not recruiting | 40 Years | N/A | All | 327 | Phase 2 | United States;Argentina;Australia;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;Czech Republic | |
| 99 | NCT02267655 | May 2015 | 16 December 2017 | 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF | An Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3) | Pulmonary Hypertension;Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary Fibrosis | Drug: inhaled Nitric Oxide - 30 mcg/kg IBW/hr;Drug: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr;Drug: inhaled nitric oxide 75 mcg/kg IBW/hr | Bellerophon | Not recruiting | 40 Years | 80 Years | All | 8 | Phase 1 | Belgium | |
| 100 | NCT02478268 | May 2015 | 27 May 2019 | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Hyperpolarized 129-Xenon gas;Device: MRI | Bastiaan Driehuys | University of Wisconsin, Madison;National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 18 Years | N/A | All | 79 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | JPRN-UMIN000016826 | 2015/03/31 | 7 October 2019 | The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. | The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. - The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis (IPF) | Pirfenidone Observation | National Hospital Organization Ibarakihigashi National Hospital | Recruiting | Not applicable | Not applicable | Male and Female | 40 | Not applicable | Japan | |
| 102 | NCT02397005 | March 2015 | 4 February 2019 | Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects | Randomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of ZL-2102 With a Pilot Investigation of Food Effect in Healthy Male Subjects | Chronic Obstructive Pulmonary Disease;Asthma;Idiopathic Pulmonary Fibrosis | Drug: ZL-2102;Drug: Placebo matching ZL-2102 | Zai Lab Pty. Ltd. | Not recruiting | 18 Years | 45 Years | Male | 120 | Phase 1 | Australia | |
| 103 | EUCTR2014-004025-40-NL | 06/02/2015 | 4 August 2015 | Treatment of chronic cough with PA101. | Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101. - Treatment of chronic cough with PA101 | Chronic Idiopathic Cough and Chronic Cough in Idiopathic Pulmonary Fibrosis MedDRA version: 18.0 Level: LLT Classification code 10066656 Term: Chronic cough System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Disodium Cromoglycate [cromolyn sodium] Product Code: PA101 Pharmaceutical Form: Nebulisation solution INN or Proposed INN: Not available CAS Number: 15826-37-6 Current Sponsor code: PA101 Other descriptive name: Disodium cromoglycate (DSCG) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Nebulisation solution Route of administration of the placebo: Inhalation use | Patara Pharma | Authorised | Female: yes Male: yes | 48 | Netherlands;United Kingdom | ||||
| 104 | NCT02412020 | February 2015 | 14 March 2016 | Treatment of Refractory Chronic Cough With PA101 | Treatment of Chronic Idiopathic Cough and Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis With PA101 | Refractory Chronic Cough | Drug: PA101;Drug: Placebo | Patara Pharma | Not recruiting | 18 Years | 75 Years | Both | 52 | Phase 2 | Netherlands;United Kingdom | |
| 105 | ChiCTR-OOC-15005841 | 2015-01-01 | 18 April 2017 | Montelukast Sodium Tablets treatment clinical study for intractable cough by idiopathic pulmonary fibrosis | Montelukast Sodium Tablets treatment clinical study for intractable cough by idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis | Montelukast Sodium Tablets treatment group :Montelukast Sodium Tablets: oral, 1 tablets each time (10mg), 1 time a day, at bedtime, for a period of 12 weeks;control group :Don't take Montelukast Sodium Tablets; | Shanghai Pulmonary Hospital | Recruiting | 50 | 80 | Both | Montelukast Sodium Tablets treatment group :30;control group :30; | Other | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | ChiCTR-OOC-15005862 | 2015-01-01 | 18 April 2017 | The clinical study of the treatment by Granulocyte colony stimulating factor for idiopathic pulmonary fibrosis. | An Open-label, parallel, randomized controlled clinical study of the treatment by Granulocyte colony stimulating factor for idiopathic pulmonary fibrosis. | idiopathic pulmonary fibrosis | treatment group:subcutaneous injection of Granulocyte colony stimulating factor termly;control group:no processing; | Shanghai Pulmonary Hospital | Recruiting | 50 | 80 | Both | treatment group:50;control group:50; | Other | China | |
| 107 | JPRN-UMIN000015508 | 2015/01/01 | 21 May 2019 | A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. | A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis | Using Micro Air nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan), patients receiving NAC combined with pirfenidone were treated twice daily with 352.4 mg of inhaled NAC, which was diluted with saline to a total volume of 6 mL for 48 weeks. Pirfenidone 1200-1800mg (control group) | Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan. | Not Recruiting | 40years-old | Not applicable | Male and Female | 150 | Not selected | Japan | |
| 108 | NCT02485886 | January 2015 | 16 December 2017 | 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis | Safety and Diagnostic Performance of 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: 68Ga-BMV101 | Peking Union Medical College Hospital | Stanford University | Not recruiting | 18 Years | N/A | All | 20 | Early Phase 1 | China |
| 109 | JPRN-JapicCTI-142708 | 24/10/2014 | 2 April 2019 | A phase II study of Lebrikizumab | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY | IDIOPATHIC PULMONARY FIBROSIS | Intervention name : RO5490255 INN of the intervention : Lebrikizumab Dosage And administration of the intervention : 250mg SC injection every 4 weeks Control intervention name : Placebo Dosage And administration of the control intervention : SC injection every 4 weeks | Chugai Pharmaceutical Co., Ltd. | 40 | BOTH | 480 | Phase 2 | ||||
| 110 | NCT04016168 | October 22, 2014 | 22 July 2019 | Idiopathic Pulmonary Fibrosis and Serum Bank | Idiopathic Pulmonary Fibrosis and Serum Bank | Idiopathic Pulmonary Fibrosis;Lung Diseases, Interstitial | Biological: Blood sample collection | Rennes University Hospital | Recruiting | 18 Years | N/A | All | 500 | N/A | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 111 | NCT02168530 | October 2014 | 14 November 2016 | A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: placebo;Drug: vismodegib | Hoffmann-La Roche | Not recruiting | 40 Years | N/A | Both | 0 | Phase 2 | Australia;France;Germany;Israel;Korea, Republic of;Mexico;Peru;United States | ||
| 112 | EUCTR2014-003423-21-BE | 29/09/2014 | 10 July 2017 | Evaluation of impact of inhaled nitric oxide on pulmonary vessel blood volume measured by high resolution computed tomography (HRCT) in subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in subjects with WHO Group 3 Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) on Long-Term Oxygen Therapy (LTOT) (Part 2). | An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects with WHO Group 3 PH associated with Idiopathic pulmonary fibrosis (IPF) on LTOT (Part 2). | Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 18.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1 Level: PT Classification code 10009033 Term: Chronic obstructive pulmonary disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1 Level: HLT Classification code 10037401 Term: Pulmonary hypertensions System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: INOmax 400ppm mol/mol inhalation gas Product Name: INO Pharmaceutical Form: Pressurised inhalation INN or Proposed INN: NITRIC OXIDE CAS Number: 10102-43-9 Current Sponsor code: IK-7002 Concentration unit: mg/kg/h milligram(s)/kilogram/hour Concentration type: up to Concentration number: 0.075- Pharmaceutical form of the placebo: Pressurised inhalation Route of administration of the placebo: Inhalation use | Bellerophon Pulse Technologies LLC | Not Recruiting | Female: yes Male: yes | Phase 1;Phase 2 | Belgium | ||||
| 113 | NCT02257177 | September 2014 | 16 December 2017 | RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients | A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Inhaled TD139;Drug: Placebo | Galecto Biotech AB | Not recruiting | 45 Years | 85 Years | All | 60 | Phase 1/Phase 2 | United Kingdom | |
| 114 | NCT02173145 | August 19, 2014 | 9 September 2019 | Azithromycin in Idiopathic Pulmonary Fibrosis | Azithromycin for the Treatment of Cough in Idiopathic Pulmonary Fibrosis- a Clinical Trial | Idiopathic Pulmonary Fibrosis;Cough | Drug: azithromycin;Drug: placebo | University Hospital Inselspital, Berne | University of Bern | Not recruiting | 18 Years | N/A | All | 27 | N/A | Switzerland |
| 115 | NCT02135380 | August 2014 | 19 February 2015 | Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis | A Prospective, Multicentric, Phase I/II, Open Label, Randomized, Interventional Study to Evaluate the Safety and Efficacy of Intravenous Autologous Adipose Derived Adult Stem Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF). | Idiopathic Pulmonary Fibrosis | Biological: Autologous Stromal Vascular Fraction (SVF);Biological: Autologous Adipose Derived MSCs (ADMSCs);Other: Control | Kasiak Research Pvt. Ltd. | Recruiting | 30 Years | 70 Years | Both | 60 | Phase 1/Phase 2 | India | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 116 | NCT02230982 | August 2014 | 25 February 2019 | Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis | Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: nintedanib | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | N/A | Brazil | ||
| 117 | NCT02141087 | July 2014 | 3 August 2015 | Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone | A Treatment Protocol to Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone | Genentech, Inc. | Not recruiting | 18 Years | N/A | Both | N/A | |||
| 118 | NCT02248064 | July 2014 | 23 February 2016 | Auto-titrating Oxygen in Chronic Respiratory Failure | The Assessment of Intelligent Oxygen Therapy (iO2t) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) | Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary Fibrosis | Device: Auto-titrating oxygen system | Imperial College London | Not recruiting | 18 Years | N/A | Both | 26 | N/A | United Kingdom | |
| 119 | NCT02622477 | June 2014 | 16 December 2017 | Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone) | Clinical Course of Treatment With ESBRIET in Patients With Mild to Moderate IPF | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone | Hoffmann-La Roche | InterMune Deutschland GmbH | Not recruiting | N/A | N/A | All | 12 | N/A | Germany |
| 120 | NCT02036970 | May 2014 | 14 January 2019 | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT | A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension | Pulmonary Arterial Hypertension;Pulmonary Hypertension;Interstitial Lung Disease;Idiopathic Interstitial Pneumonia;Idiopathic Pulmonary Fibrosis;Sarcoidosis;Respiratory Bronchiolitis Associated Interstitial Lung Disease;Desquamative Interstitial Pneumonia;Cryptogenic Organizing Pneumonia;Acute Interstitial Pneumonitis;Idiopathic Lymphoid Interstitial Pneumonia;Idiopathic Pleuroparenchymal Fibroelastosis | Drug: Bardoxolone methyl;Drug: Placebo | Reata Pharmaceuticals, Inc. | Not recruiting | 18 Years | 75 Years | All | 166 | Phase 2 | United Kingdom;Spain;United States;Germany | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 121 | NCT02171156 | May 2014 | 16 December 2017 | Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP) | Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: nintedanib | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | N/A | United States | ||
| 122 | NCT02048644 | March 2014 | 22 July 2019 | Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment With Fostair® Pressurized Metered-dose Inhaler (pMDI) 200/12 on Biomarkers of Platelet Adhesion in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: placebo;Drug: fostair | Hull and East Yorkshire Hospitals NHS Trust | Chiesi Farmaceutici S.p.A. | Not recruiting | 40 Years | 85 Years | All | 20 | Phase 2 | United Kingdom |
| 123 | NCT02055456 | February 2014 | 14 December 2015 | Nandrolone Decanoate in the Treatment of Telomeropathies | Male Hormones for Telomere Related Diseases | Aplastic Anemia;Bone Marrow Failure Syndromes;Idiopathic Pulmonary Fibrosis;Telomere Shortening | Drug: Nandrolone Decanoate | University of Sao Paulo | Conselho Nacional de Desenvolvimento Científico e Tecnológico | Recruiting | 2 Years | N/A | Both | 20 | Phase 1/Phase 2 | Brazil |
| 124 | NCT01969409 | January 2014 | 4 March 2019 | Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis | Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF) | Ambulatory IPF | Drug: Rituximab;Drug: Placebo | University of Alabama at Birmingham | National Institutes of Health (NIH) | Not recruiting | 50 Years | 85 Years | All | 58 | Phase 2 | United States |
| 125 | NCT02036580 | January 2014 | 16 December 2017 | D2212C00002 J-Phase II Study | A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: tralokinumab cohort 1;Biological: tralokinumab cohort 2;Other: Placebo | AstraZeneca | MedImmune LLC | Not recruiting | 50 Years | N/A | All | 37 | Phase 2 | Japan |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 126 | NCT02009293 | December 2013 | 9 January 2017 | The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis | Observational Study of the Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Other: Cough monitor | Erasmus Medical Center | University of Catania;University of Lyon;King's College Hospital NHS Trust;Royal Brompton & Harefield NHS Foundation Trust | Not recruiting | 40 Years | 85 Years | Both | 43 | N/A | France;Italy;Netherlands |
| 127 | NCT01979952 | November 26, 2013 | 11 June 2018 | Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months | Idiopathic Pulmonary Fibrosis | Drug: Matching Placebo;Drug: Nintedanib | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 113 | Phase 3 | United States;Canada;Turkey | |
| 128 | NCT01777737 | November 25, 2013 | 16 December 2017 | Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole | Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Cotrimoxazole;Drug: Placebo | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Junta de Andalucia | Not recruiting | 18 Years | 80 Years | All | 3 | Phase 3 | Spain |
| 129 | NCT02013700 | November 13, 2013 | 18 March 2019 | Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) | A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs);Biological: matched placebo | Joshua M Hare | The Lester And Sue Smith Foundation;The EMMES Corporation | Not recruiting | 40 Years | 90 Years | All | 9 | Phase 1 | United States |
| 130 | JPRN-UMIN000021109 | 2013/10/21 | 10 September 2019 | Preventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancer | Preventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancer - Preventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancer (Sivelestat trial) | idiopathic interstitial pneumonia (IIP) | Control (n=30): intra- and postoperative management without Sivelestat Trial (n=30): 7days administration of Sivelestat 0.2microgram/kgBW/hr div started from surgical operation | Japanese Northern East Area Thoracic Surgery Study Group (JNETS) | Not Recruiting | 25years-old | 80years-old | Male and Female | 120 | Phase 3 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 131 | NCT01872689 | October 13, 2013 | 3 September 2018 | A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Lebrikizumab;Drug: Pirfenidone;Drug: Placebo | Hoffmann-La Roche | Not recruiting | 40 Years | N/A | All | 505 | Phase 2 | United States;Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom | |
| 132 | EUCTR2013-003301-26-GB | 20/09/2013 | 3 April 2017 | A clinical trial to assess whether a treatment reducing acid production in the stomach (omeprazole) can reduce cough in patients with scarring of the lungs. | A randomised placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF) - Pilot trial of omeprazole in idiopathic pulmonary fibrosis (Acronym : | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Omeprazole (UK licensed generic product) Product Name: Omeprazole Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Omeprazole CAS Number: 73590-58-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Newcastle Upon Tyne Hospitals NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | Phase 2 | United Kingdom | ||||
| 133 | EUCTR2012-000564-14-BE | 18/06/2013 | 17 August 2015 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone - PANORAMA | Patients with Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 17.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fluimucil® 600 mg effervescent tablets Pharmaceutical Form: Effervescent tablet INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: N-Acetylcysteine, (NAC) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600- Pharmaceutical form of the placebo: Effervescent tablet Route of administration of the placebo: Oral use | InterMune International AG. | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Belgium;Denmark;Austria;Germany;United Kingdom;Italy;Sweden | |||
| 134 | NCT01890265 | June 2013 | 13 May 2019 | Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: FG-3019;Drug: Placebo;Drug: Sub-study: Pirfenidone;Drug: Sub-study: Nintedanib;Drug: Sub-study: FG-3019;Drug: Sub-study: Placebo | FibroGen | Not recruiting | 40 Years | 80 Years | All | 160 | Phase 2 | United States;Australia;Bulgaria;Canada;India;New Zealand;South Africa | |
| 135 | EUCTR2012-005409-38-ES | 19/04/2013 | 11 December 2017 | First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole. | Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis | Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis. MedDRA version: 14.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Parasitic Diseases [C03] | Trade Name: SEPTRIN Pharmaceutical Form: Tablet INN or Proposed INN: TRIMETHOPRIM Other descriptive name: TRIMETHOPRIM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 80- INN or Proposed INN: SULFAMETHOXAZOLE CAS Number: 723-46-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) | Not Recruiting | Female: yes Male: yes | 56 | Phase 3 | Spain | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 136 | EUCTR2012-005794-31-GB | 25/03/2013 | 18 November 2013 | A study to assess the effect of a single-does of VRP700 by inhalation to reduce the frequency and severity of cough in adults with Idiopathic Pulmonary Fibrosis (IPF) | A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis - EPOCh | Chronic cough in Idiopathic Pulmonary Fibrosis MedDRA version: 16.1 Level: LLT Classification code 10066656 Term: Chronic cough System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 16.1 Level: PT Classification code 10011224 Term: Cough System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: VRP700 Product Code: VRP700 Pharmaceutical Form: Inhalation powder Current Sponsor code: VRP700 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Inhalation vapour, solution Route of administration of the placebo: Inhalation use | Verona Pharma plc | Authorised | Female: yes Male: yes | United Kingdom | |||||
| 137 | NCT01725139 | March 8, 2013 | 16 December 2017 | A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Randomised, Placebo-controlled, Double-blind, Repeat Dose Escalation Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: GSK2126458;Drug: Placebo | GlaxoSmithKline | Not recruiting | 45 Years | N/A | All | 17 | Phase 1 | United Kingdom | |
| 138 | NCT01919827 | March 2013 | 11 June 2018 | Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis | Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells | Idiopathic Pulmonary Fibrosis | Biological: Endobronchial infusion of adult mesenchymal stem cells;Biological: Autologous mesenchymal stem cells derived from bone marrow | Clinica Universidad de Navarra, Universidad de Navarra | Not recruiting | 30 Years | 80 Years | All | 17 | Phase 1 | Spain | |
| 139 | NCT02594839 | February 2013 | 22 January 2018 | Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease | A Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease | Idiopathic Interstitial Pneumonia;Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis | Drug: Bone marrow mesenchymal stem cells;Drug: Placebo | Federal Research Clinical Center of Federal Medical & Biological Agency, Russia | Not recruiting | 20 Years | 80 Years | All | 20 | Phase 1/Phase 2 | Russian Federation | |
| 140 | NCT01766817 | January 31, 2013 | 26 August 2019 | Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis | Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: BMS-986020;Drug: Placebo matching with BMS-986020 | Bristol-Myers Squibb | Not recruiting | 40 Years | 90 Years | All | 325 | Phase 2 | United States;Australia;Chile;Colombia;Mexico;Peru | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 141 | NCT01769196 | January 31, 2013 | 16 December 2017 | Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Simtuzumab;Drug: Simtuzumab placebo | Gilead Sciences | Not recruiting | 45 Years | 85 Years | All | 544 | Phase 2 | United States;Australia;Belgium;Canada;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;Czech Republic | |
| 142 | JPRN-jRCTs051180149 | 24/01/2013 | 22 July 2019 | CBDCA plus PTX for NSCLC (squamous) with IP | Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia - IP001 | Squamous cell lung cancer Lung cancer | Carboplatin (AUC=5) given on day1 and paclitaxel (70mg/m2) given on days 1,8,15 every 4weeks until disease progression or unmanageable toxicity. | Yukimasa Hatachi | Not Recruiting | >=20 age old | Both | 40 | Phase 2 | none | ||
| 143 | JPRN-jRCTs061180046 | 17/01/2013 | 22 July 2019 | CBDCA, PTX and BV for NSCLC (non-sq) with IP | Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia - IP002 | Non-squamous, non-small cell lung cancer Lung cancer | Carboplatin (AUC=5) given on day1, paclitaxel (70mg/m2) given on days 1,8,15 and bevacizumab (15mg/m2) on day 1 every 4weeks until disease progression or unmanageable toxicity. | Yukimasa Hatachi | Not Recruiting | 20 year-old age old | Not applicable age old | Both | 35 | Phase 2 | none | |
| 144 | JPRN-UMIN000016706 | 2013/01/07 | 2 April 2019 | Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis | N-acetylcysteine was administered by inhalation at the dose of 352.4 mg b.i.d. via an ultrasonic nebulizer. | Saitama Red Cross Hospital | Not Recruiting | 40years-old | Not applicable | Male and Female | 25 | Not selected | Japan | ||
| 145 | JPRN-UMIN000018248 | 2012/12/01 | 2 April 2019 | Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia | advanced squamous cell lung cancer with idiopathic interstitial pneumonia | Carboplatin AUC = 5 , day1 Paclitaxel 70mg/m2, day1,8,15 4-6 cycle | IP lung cancer study group | Recruiting | 20years-old | Not applicable | Male and Female | 40 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 146 | JPRN-UMIN000018322 | 2012/12/01 | 2 April 2019 | Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia | advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia | carboplatin AUC = 5, day1 paclitaxel 70mg/m2, day1 ,8 ,15 bevacizumab 15mg/kg, day1 every 4 weeks, 4-6 cycle | IP lung cancer study group | Recruiting | 20years-old | Not applicable | Male and Female | 35 | Not selected | Japan | ||
| 147 | NCT01759511 | October 18, 2012 | 16 December 2017 | Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) | A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Simtuzumab | Gilead Sciences | Not recruiting | 18 Years | N/A | All | 34 | Phase 2 | United States | |
| 148 | NCT01629667 | October 2012 | 16 December 2017 | A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis | A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: Tralokinumab;Other: Placebo | MedImmune LLC | Not recruiting | 50 Years | 79 Years | All | 409 | Phase 2 | United States;Australia;Canada;Israel;Korea, Republic of;Peru | |
| 149 | NCT01524068 | September 2012 | 18 January 2016 | A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations | A Multicenter, Open-Label, Phase II Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations | Idiopathic Pulmonary Fibrosis | Drug: Standard Steroid Treatment;Drug: The Standard Steroid Treatment, Plasma Exchange and rituximab | University of Pittsburgh | Not recruiting | 18 Years | 90 Years | Both | 0 | Phase 2 | United States | |
| 150 | JPRN-UMIN000008541 | 2012/07/30 | 2 April 2019 | The effect of pirfenidone on the mortality risk score in IPF | idiopathic pulmonary fibrosis | pirfenidone | Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 151 | NCT01371305 | July 16, 2012 | 11 June 2018 | STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) | Drug: BG00011;Drug: Placebo | Biogen | Not recruiting | 18 Years | 84 Years | All | 41 | Phase 2 | United States | |
| 152 | NCT01619085 | June 6, 2012 | 30 September 2019 | Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis | An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: BIBF 1120 | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 752 | Phase 3 | United States;Australia;Belgium;Canada;Chile;China;Czechia;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;Czech Republic | |
| 153 | JPRN-UMIN000007774 | 2012/06/01 | 2 April 2019 | Phase II analysis for efficacy and safety of perioperative pirfenidone (Pirespa) therapy for patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis (IPF) | non-small-cell lung cancer combined with idiopathic pulmonary fibrosis | Oral administration of pirfenidone starting from 4-6 weeks before the surgery. | West Japan Oncology Group | Not Recruiting | 20years-old | 75years-old | Male and Female | 42 | Phase 2 | Japan | ||
| 154 | EUCTR2011-002766-21-GR | 02/05/2012 | 22 January 2018 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft INN or Proposed INN: nintedanib Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Boehringer Ingelheim Hellas | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Chile;Russian Federation;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | |||
| 155 | NCT01457261 | April 2012 | 19 February 2015 | IPF Drug Deposition Study | A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF) | Idiopathic Pulmonary Fibrosis | Drug: Salbutamol | Royal Brompton & Harefield NHS Foundation Trust | GlaxoSmithKline | Not recruiting | 40 Years | N/A | Both | 10 | Phase 1 | United Kingdom |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 156 | NCT01529853 | April 2012 | 19 February 2015 | To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: SAR156597;Drug: Placebo | Sanofi | Not recruiting | 18 Years | N/A | Both | 24 | Phase 1/Phase 2 | United States;Canada;Chile;Mexico;Spain;Belgium | |
| 157 | EUCTR2011-003687-78-IT | 21/02/2012 | 24 February 2014 | Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) | Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) - IPF/LANREOTIDE/2011-01 | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Pharmaceutical Form: Solution for injection INN or Proposed INN: LANREOTIDE ACETATE CAS Number: 127984-74-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Product Name: Gallium68-Dota-Noc Product Code: NA Pharmaceutical Form: Solution for injection INN or Proposed INN: NA CAS Number: NA Current Sponsor code: 68Gallio-DOTA-NOC Other descriptive name: NA Concentration unit: MBq megabecquerel(s) Concentration type: up to Concentration number: 185- | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | Authorised | Female: yes Male: yes | Italy | |||||
| 158 | NCT02699879 | February 16, 2012 | 16 December 2017 | Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone | Hoffmann-La Roche | Not recruiting | N/A | N/A | All | 1009 | N/A | Austria;Denmark;Finland;France;Germany;Ireland;Italy;Norway;Sweden;United Kingdom | |
| 159 | NCT01504334 | January 2012 | 19 February 2015 | Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF) | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for the Safety and Efficacy of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone;Drug: Placebo | Beijing Kawin Technology Share-Holding Co., Ltd. | Recruiting | 18 Years | 75 Years | Both | 80 | Phase 2 | China | |
| 160 | NCT02136992 | December 2011 | 19 February 2015 | Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone;Drug: placebo | Shanghai Pulmonary Hospital, Shanghai, China | Nanjing Chia-tai Tianqing Pharmaceutical | Not recruiting | N/A | 75 Years | Both | 160 | Phase 2 | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 161 | NCT01382368 | September 2011 | 19 February 2015 | Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients | Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients | Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary Fibrosis | Drug: Sildenafil | Rabin Medical Center | Recruiting | 30 Years | 90 Years | Both | 60 | Phase 4 | Israel | |
| 162 | NCT01417156 | September 2011 | 16 December 2017 | Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) | A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Drug: Nintedanib;Drug: Pirfenidoneone | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 20 | Phase 2 | Japan | |
| 163 | NCT01432080 | September 2011 | 16 December 2017 | Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant | Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study | Respiratory Tract Infections;Bronchiolitis Obliterans;Cryptogenic Organizing Pneumonia;Lung Diseases, Interstitial | Drug: Prednisone;Drug: Azithromycin;Drug: Montelukast;Drug: Symbicort | Maisonneuve-Rosemont Hospital | The Canadian Blood and Marrow Transplant Group | Not recruiting | 18 Years | N/A | All | 12 | Phase 2 | Canada |
| 164 | NCT01214187 | July 2011 | 16 December 2017 | Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis | Phase II Study of Inhaled CO for the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: inhaled carbon monoxide;Other: Oxygen | Brigham and Women's Hospital | National Heart, Lung, and Blood Institute (NHLBI);University of California, San Francisco;University of Chicago;University of Illinois at Chicago;University of Michigan;Columbia University;Tulane University;University of Washington | Not recruiting | 18 Years | 85 Years | All | 58 | Phase 2 | United States |
| 165 | NCT01346930 | July 2011 | 19 February 2015 | Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis | Long Term, Single-arm, Open-label Extension Study of the MUSIC Study to Assess the Safety and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Macitentan | Actelion | Not recruiting | 18 Years | N/A | Both | 0 | Phase 2 | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 166 | EUCTR2010-023828-24-GB | 09/06/2011 | 27 May 2013 | The effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF cough | The effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF cough | Cough in Idiopathic Pulmonary fibrosis. | Trade Name: Thalidomide Pharmion Product Name: Thalidomide Pharmion Pharmaceutical Form: Capsule Trade Name: PREDNISOLONE Product Name: prednisolone Pharmaceutical Form: Tablet | University of Nottingham | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
| 167 | NCT01366209 | June 2011 | 16 December 2017 | Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial) | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone;Drug: Placebo | Genentech, Inc. | Not recruiting | 40 Years | 80 Years | All | 555 | Phase 3 | United States | |
| 168 | EUCTR2010-024211-13-SE | 26/05/2011 | 19 March 2012 | Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC study | Long term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC OL | Patients with Idiopathic Pulmonary Fibrosis MedDRA version: 13.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Macitentan Product Code: ACT-064992 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: macitentan CAS Number: 441798-33-0 Current Sponsor code: ACT-064992 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | ACTELION Pharmaceuticals Ltd. | Authorised | Female: yes Male: yes | 178 | Germany;Canada;Turkey;Spain;United States;South Africa;Australia;Sweden;Israel | ||||
| 169 | EUCTR2010-024251-87-DE | 12/04/2011 | 3 February 2014 | Safety and Efficacy of BIBF 1120 at high dose in Idiopathic Pulmonary Fibrosis patients | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Boehringer Ingelheim Pharma GmbH & Co. KG | Not Recruiting | Female: yes Male: yes | 485 | United States;Ireland;Israel;Italy;United Kingdom;India;France;Czech Republic;Argentina;Belgium;Brazil;Australia;Germany;Japan;China | ||||
| 170 | EUCTR2010-024252-29-FI | 01/04/2011 | 16 December 2013 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 12.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Boehringer Ingelheim | Not Recruiting | Female: yes Male: yes | 485 | Portugal;Greece;Finland;Spain;Netherlands;Germany | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 171 | NCT01262001 | March 2011 | 14 October 2019 | Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis | A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: FG-3019 | FibroGen | Not recruiting | 35 Years | 80 Years | All | 90 | Phase 2 | United States | |
| 172 | NCT01265888 | March 2011 | 26 September 2016 | Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. | A Phase 2, Open-Label, Dose-Escalation Study in Subjects With Pulmonary Arterial Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) Using Inhaled GeNOsyl. | Pulmonary Arterial Hypertension;Idiopathic Pulmonary Fibrosis | Drug: Inhaled Nitric Oxide | Geno LLC | Not recruiting | 18 Years | 80 Years | Both | 31 | Phase 2 | United States | |
| 173 | NCT01266317 | March 2011 | 18 January 2016 | Combined PEX, Rituximab and Steroids in Acute IPF Exacerbations | Open-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations | IPF | Drug: Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids | University of Pittsburgh | Not recruiting | 18 Years | 80 Years | Both | 10 | Phase 1/Phase 2 | United States | |
| 174 | ChiCTR-TRC-12002372 | 2011-02-23 | 18 April 2017 | Levofloxacin (Cravit) versus Moxifloxacin-concentration of epithelial lining fluid in patients with idiopathic pulmonary fibrosis (IPF) | Levofloxacin (Cravit) versus Moxifloxacin-concentration of epithelial lining fluid in patients with idiopathic pulmonary fibrosis | idiopathic pulmonary fibrosis | Cravit IPF Group:Cravit 500 mg per time;Cravit Normal Pulmonary Function Group:Cravit 500 mg per time;Moxifloxacin IPF Group:Moxifloxacin 400mg per time;Moxifloxacin Normal PulmonaryFunction Group:Moxifloxacin 400mg per time; | Respiratory Department, Peking Union Medical College Hospital | Not Recruiting | 18 | 70 | Both | Cravit IPF Group:12;Cravit Normal Pulmonary Function Group:12;Moxifloxacin IPF Group:12;Moxifloxacin Normal PulmonaryFunction Group:12; | Other | China | |
| 175 | JPRN-UMIN000005098 | 2011/02/01 | 2 April 2019 | A randomized trial of ambulatory oxygen in patients with idiopathic pulmonary fibrosis and desaturation but without resting hypoxemia | idiopathic pulmonary fibrosis | ambulatory oxygen ambulatory air | Department of Respiratory Medicine and Allergology, Kinki University School of Medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 176 | JPRN-UMIN000004749 | 2011/01/01 | 2 April 2019 | A study to evaluate the long-term effect of pulmonary hypertension on prognosis, activities of daily living (ADL), cardiac function and pulmonary function in patients with COPD and idiopathic pulmonary fibrosis (IPF), respectively, according to baseline severity of pulmonary hypertension and the efficacy and safety of the Tracleer (bosentan hydrate) tablet for prognosis, activities of daily living, cardiac function and pulmonary function in patients with COPD and IPF, respectively, according to baseline severity of pulmonary hypertension. | Patients with COPD or IPF (WHO functional class II, III or IV), without hypoxia (PaO2 at rest<90mmHg or after 6minutes walk), who provide their informed consent to participate in this study. | Treated subgroup In patients with COPD without hypoxia (PaO2<60mmHg at rest or after 6 minutes walk) (WHO functional class II, III or IV), patients with Pulmonary hypertension with evidense of mPAP at rest=/>35mmHg : 20subjects Bosentan will be administered basically according to the approved dosage and administration, as specified below. However, in this study conducted in accordance with routine clinical practice, the initial dosage may be used continuously if considered appropriate based on the patient's condition. Treatment with bosentan in adults is usually initiated at a dose of 62.5 mg twice daily to be taken orally after breakfast and the evening meal for 4 weeks. From Week 5 of treatment, bosentan is administered at a dose of 125 mg twice daily to be taken orally after breakfast and evening meal. The dosage should be adjusted according to the patient's symptoms and tolerability, but should not exceed 250 mg per day. Duration of study drug administration: 24 months In addition, Interventions/Control 11 and 12 is described in Interventions/control 10. Treated subgroup In patients with COPD without hypoxia (PaO2<60mmHg at rest or after 6 minutes walk) (WHO functional class II, III or IV), patients with boarderline pulmonary hypertension or pulmonary hypertension (mPAP at rest=/>25mmHg and/or mPAP on effort=/>30mmHg) with mPAP at rest<35mmHg: 20subjects Tracleer Tablets will be administered basically according to the approved dosage and administration, as specified below. However, in this study conducted in accordance with routine clinical practice, the initial dosage may be used continuously if considered appropriate based on the patient's condition. Treatment with bosentan in adults is usually initiated at a dose of 62.5 mg twice daily to be taken orally after breakfast and the evening meal for 4 weeks. From Week 5 of treatment, bosentan is administered at a dose of 125 mg twice daily to be taken orally after breakfast and even | Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School | Recruiting | 40years-old | Not applicable | Male and Female | 160 | Not applicable | Japan | ||
| 177 | NCT01203943 | January 2011 | 19 February 2015 | A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) | A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis;Pulmonary Fibrosis;Fibrosis;Interstitial Lung Disease;Lung Diseases, Interstitial | Drug: CC-930;Other: Placebo | Celgene Corporation | Not recruiting | 50 Years | N/A | Both | 28 | Phase 2 | United States;Canada | |
| 178 | NCT01254409 | January 2011 | 19 October 2017 | A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Randomized, Double-Masked, Sponsor-Unmasked, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRM-151 Administered Intravenously to Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: PRM-151;Other: Placebo | Promedior, Inc. | Not recruiting | 40 Years | 80 Years | All | 21 | Phase 1 | United States;Netherlands | |
| 179 | NCT01280994 | January 2011 | 23 April 2019 | Hyperpolarized 129Xe MRI for Imaging Pulmonary Function | Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease | Interstitial Lung Disease;Cystic Fibrosis;Pulmonary Hypertension;NSIP;Alpha 1-Antitrypsin Deficiency | Drug: Xenon | Bastiaan Driehuys | Recruiting | 18 Years | 80 Years | All | 445 | Phase 1 | United States | |
| 180 | NCT01266135 | December 2010 | 28 April 2015 | Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to Assess the Safety, Tolerability, Efficacy, Pharmacodynamic (PD) and Pharmacokinetics of QAX576 in Patients With Rapidly Progressive IPF | Idiopathic Pulmonary Fibrosis | Drug: QAX576;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 80 Years | Both | 40 | Phase 2 | United States;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 181 | NCT01362231 | December 2010 | 3 August 2015 | A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: GS-6624 | Gilead Sciences | Not recruiting | 40 Years | 85 Years | Both | 48 | Phase 1 | United States | |
| 182 | EUCTR2008-004405-34-CZ | 13/09/2010 | 18 April 2012 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ambrisentan CAS Number: 177036-94-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Letairis 10 mg Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ambrisentan CAS Number: 177036-94-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Gilead Sciences Incorporated | Not Recruiting | Female: yes Male: yes | 660 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | |||
| 183 | NCT01199887 | September 2010 | 19 February 2015 | Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis | A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: IW001 | ImmuneWorks | Not recruiting | 35 Years | 75 Years | Both | 30 | Phase 1 | United States | |
| 184 | EUCTR2010-020223-44-AT | 03/08/2010 | 19 March 2012 | (18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia | (18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia | Interstitial lung disease of unknown etiology | Trade Name: (18)F-FDG Product Name: (18)F-FDG Pharmaceutical Form: Solution for injection INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE CAS Number: 105851-17-0 Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 300 MBq- | Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik | Authorised | Female: yes Male: yes | Austria | |||||
| 185 | NCT01135199 | June 2010 | 20 April 2015 | Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis | Safety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study | Pulmonary Fibrosis | Drug: pomalidomide (CC-4047 | Stanford University | Celgene Corporation | Not recruiting | 18 Years | N/A | Both | 0 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 186 | NCT01136174 | May 2010 | 19 October 2017 | Safety and PK Study of BIBF 1120 in Japanese Patients With IPF | A Double-blind, Randomised, Placebo-controlled (Within a Dose Group) Study to Evaluate Safety and Pharmacokinetics of Multiple Rising Doses of BIBF 1120 at 50 mg Bid (14 Days), 100 mg Bid (14 Days), and 150 mg Bid (28 Days) p.o., on Top of Standard Medical Care With Stratification According to Pirfenidone Use, in Japanese Patients With Idiopathic Pulmonary Fibrosis. | Idiopathic Pulmonary Fibrosis | Drug: Placebo;Drug: BIBF 1120 | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 50 | Phase 2 | Japan | |
| 187 | EUCTR2009-013788-21-ES | 28/04/2010 | 19 October 2015 | Ensayo clínico de Fase II, abierto, y de extensión para evaluar la tolerabilidad a largo plazo, la seguridad y la eficacia de BIBF 1120 administrado por vía oral en pacientes con Fibrosis Pulmonar Idiopática A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | Ensayo clínico de Fase II, abierto, y de extensión para evaluar la tolerabilidad a largo plazo, la seguridad y la eficacia de BIBF 1120 administrado por vía oral en pacientes con Fibrosis Pulmonar Idiopática A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | Fibrosis Pulmonar Idiopática MedDRA version: 12.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Boehringer Ingelheim España S.A. | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;United Kingdom;Italy | |||
| 188 | EUCTR2009-013788-21-BE | 22/04/2010 | 28 November 2016 | A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 17.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | SCS Boehringer Ingelheim Comm.V | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Spain;Belgium;Ireland;Bulgaria;Germany;United Kingdom;Italy | |||
| 189 | EUCTR2009-011169-98-DE | 03/11/2009 | 19 March 2012 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis MedDRA version: 12.0 Level: LLT Classification code 10037400 Term: Pulmonary hypertension | Trade Name: Letairis Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ambrisentan CAS Number: 177036-94-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Letairis Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ambrisentan CAS Number: 177036-94-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Gilead Sciences, Inc | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;United Kingdom;Germany;Italy;Austria | |||
| 190 | JPRN-UMIN000005793 | 2009/11/01 | 2 April 2019 | Open-label study of tiotropium/pirfenidone for idiopathic pulmonary fibrosis with emphysema | Idiopathic pulmonary fibrosis (IPF) with centrilobular emphysema (CLE) | tiotropium for 8 weeks and then tiotropium + pirfenidone for 44 weeks pirfenidone 44 weeks and then tiotropium + pirfenidone for 8 weeks | Saitama Medical University | Recruiting | 40years-old | Not applicable | Male and Female | 60 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 191 | JPRN-UMIN000016045 | 2009/10/03 | 21 May 2019 | A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. | A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis | Using Micro Air nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan), patients receiving NAC combined with pirfenidone were treated twice daily with 352.4 mg of inhaled NAC, which was diluted with saline to a total volume of 6 mL for 48 weeks. Pirfenidone 1200-1800mg (control group) | Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | |
| 192 | NCT00957242 | October 2009 | 19 October 2017 | AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis | AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF) | Idiopathic Pulmonary Fibrosis | Drug: warfarin;Drug: placebo | Duke University | National Heart, Lung, and Blood Institute (NHLBI);Duke Clinical Research Institute | Not recruiting | 35 Years | 80 Years | All | 145 | Phase 3 | United States |
| 193 | NCT00981747 | September 2009 | 16 December 2017 | Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis | A Clinical Treatment Trial Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Pulmonary Fibrosis | Drug: Sildenafil;Drug: Losartan;Drug: Sildenafil and Losartan;Drug: Placebo pill | University of Iowa | Pulmonary Fibrosis Foundation | Not recruiting | 18 Years | 99 Years | All | 16 | Phase 2/Phase 3 | United States |
| 194 | NCT00879229 | July 2009 | 19 October 2017 | ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension | Idiopathic Pulmonary Fibrosis;Pulmonary Hypertension | Drug: Ambrisentan;Drug: Placebo | Gilead Sciences | Not recruiting | 35 Years | 80 Years | All | 40 | Phase 3 | United States;Australia;Austria;Canada;Germany;Italy;United Kingdom;Belgium;Ireland;Israel | |
| 195 | NCT00903331 | May 2009 | 19 October 2017 | Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study | A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: ACT-064992 (macitentan);Drug: Placebo | Actelion | Not recruiting | 18 Years | N/A | All | 178 | Phase 2 | United States;Australia;Canada;France;Germany;Israel;Italy;Slovenia;South Africa;Spain;Sweden;Turkey | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 196 | NCT00879879 | March 2009 | 19 October 2017 | Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis | Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project | Precancerous Condition | Drug: losartan | University of South Florida | National Cancer Institute (NCI) | Not recruiting | 21 Years | N/A | All | 20 | N/A | United States |
| 197 | EUCTR2008-007168-40-IT | 20/01/2009 | 19 March 2012 | Use of 68Ga-DOTA-NOC for the evaluation of patients with Idiopathic pulmonary fibrosis STUDY CODE: 68Ga-DOTA-NOC/ILD 01/2008 - 68Ga-DOTA-NOC/ILD01/2008 | Use of 68Ga-DOTA-NOC for the evaluation of patients with Idiopathic pulmonary fibrosis STUDY CODE: 68Ga-DOTA-NOC/ILD 01/2008 - 68Ga-DOTA-NOC/ILD01/2008 | patients with Idiopathic pulmonary fibrosis MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Product Name: Gallium68-Dota-Noc Pharmaceutical Form: Solution for injection Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 185- | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | Authorised | Female: yes Male: yes | Italy | |||||
| 198 | EUCTR2008-001281-86-NL | 14/01/2009 | 19 March 2012 | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Product Name: CNTO888 Product Code: CNTO888 Pharmaceutical Form: Powder for solution for infusion Current Sponsor code: CNTO888 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Centocor B.V. | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Germany;Netherlands;Belgium | |||
| 199 | JPRN-UMIN000025256 | 2009/01/01 | 2 April 2019 | Benefits of supplemental oxygen on exercise capacity and dyspnea in IPF patients | idiopathic pulmonary fibrosis | oxygen gas air gas | Tosei General Hospital | Not Recruiting | Not applicable | 75years-old | Male and Female | 106 | Not applicable | Japan | ||
| 200 | NCT00768300 | December 2008 | 19 October 2017 | (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF | ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Ambrisentan;Drug: Placebo | Gilead Sciences | Not recruiting | 40 Years | 80 Years | All | 494 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;France;Germany;Ireland;Israel;Italy;Mexico;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 201 | NCT00786201 | December 2008 | 19 February 2015 | A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Drug: Placebo;Drug: CNTO 888 1 mg/kg;Drug: CNTO 888 5 mg/kg;Drug: CNTO 888 15 mg/kg | Centocor, Inc. | Not recruiting | 40 Years | 80 Years | Both | 126 | Phase 2 | United States;Belgium;Canada;Germany;Netherlands | |
| 202 | JPRN-UMIN000013559 | 2008/10/01 | 2 April 2019 | A prospective and multicenter trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis | Patients were treated with intravenous immunoglobulin (IVIG) at 0.4 g/kg/day for 5 consecutive days (5-day IVIG group) Patients were treated with intravenous immunoglobulin (IVIG) at 0.4 g/kg/day once-monthly for 5 consecutive months (5-month IVIG group) | Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine | Not Recruiting | 50years-old | 75years-old | Male and Female | 10 | Not applicable | Japan | ||
| 203 | NCT00662038 | August 2008 | 16 December 2017 | Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) | An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: pirfenidone | Genentech, Inc. | Hoffmann-La Roche | Not recruiting | 40 Years | 84 Years | All | 1058 | Phase 3 | United States |
| 204 | NCT00705133 | July 2008 | 11 June 2018 | Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension | Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease | Pulmonary Arterial Hypertension;Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis | Drug: Treprostinil | Rajan Saggar | United Therapeutics | Not recruiting | N/A | N/A | All | 15 | Phase 2 | United States |
| 205 | EUCTR2007-001741-18-FR | 24/06/2008 | 18 April 2012 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: BOSENTAN CAS Number: 147536978 Current Sponsor code: Ro 47-0203 Other descriptive name: Tracleer Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 62.5- Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: BOSENTAN CAS Number: 147536978 Current Sponsor code: Ro 47-0203 Other descriptive name: Tracleer Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- | Actelion Pharmaceuticals Ltd | Authorised | Female: yes Male: yes | 390 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 206 | EUCTR2007-007800-13-IE | 04/06/2008 | 23 January 2017 | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pirfenidone Current Sponsor code: 53179-13-8 Other descriptive name: PIR, S-7701 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 267- | InterMune, Inc. | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | France;Belgium;Germany;Italy;United Kingdom;Ireland;Spain | |||
| 207 | NCT00690885 | June 2008 | 19 February 2015 | Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis | Evaluation of Natural Human Interferon Alpha Lozenges in the Treatment of Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF) | Pulmonary Disease, Chronic Obstructive;Pulmonary Fibrosis;Cough | Drug: interferon-alpha lozenges;Drug: placebo lozenges | Amarillo Biosciences, Inc. | Texas Tech University Health Sciences Center | Not recruiting | 40 Years | N/A | Both | 1 | Phase 2 | United States |
| 208 | NCT00703339 | June 2008 | 11 June 2018 | Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | A Single-Dose, Dose-Escalating Study Exploring the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Inhaled Treprostinil Sodium Using the Nebu-Tec OPTINEB Inhalation Device in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Pulmonary Hypertension | Drug: Treprostinil sodium for inhalation | Lung Biotechnology PBC | Not recruiting | 35 Years | 80 Years | All | 1 | Phase 2 | United States | |
| 209 | NCT00631475 | April 2008 | 19 October 2017 | Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 | Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443) | Idiopathic Pulmonary Fibrosis | Drug: Bosentan | Actelion | Not recruiting | 18 Years | N/A | All | 128 | Phase 3 | United States;Australia;Belgium;Canada;Czech Republic;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Spain;Switzerland;United Kingdom;Austria;Croatia;Former Serbia and Montenegro;Netherlands;Serbia | |
| 210 | EUCTR2008-006054-17-DE | 22 October 2012 | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC | To evaluate the efficacy, safety, and tolerabilitiy of macitentan in patients with idiopathic pulmonary fibrosis. MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Product Name: macitentan Product Code: ACT-064992 Pharmaceutical Form: Tablet INN or Proposed INN: macitentan CAS Number: 441798-33-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Actelion Pharmaceuticals Ltd. | Not Recruiting | Female: yes Male: yes | 156 | France;Slovenia;Spain;Germany;Italy;Sweden | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 211 | EUCTR2007-001645-17-GB | 04/12/2007 | 19 March 2012 | Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung Disease | Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung Disease | Pulmonary hypertension in patients with interstitial lung disease. Specifically this trial looks at patients who have mild pulmonary hypertension, or are in an at-risk group to developing pulmonary hypertension, in the context of their interstitial lung disease. The interstitial lung diseases addressed include idiopathic pulmonary fibrosis and non-specific interstitial pneumonitis. MedDRA version: 9.1 Level: LLT Classification code 10064911 Term: Pulmonary arterial hypertension | Trade Name: Tracleer Product Name: Tracleer Pharmaceutical Form: Film-coated tablet Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Royal Brompton and Harefield NHS Trust | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
| 212 | NCT00600028 | December 2007 | 16 December 2017 | Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide | Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide | Idiopathic Pulmonary Fibrosis;Cough | Drug: Thalidomide;Drug: Placebo | Johns Hopkins University | Not recruiting | 50 Years | N/A | All | 25 | Phase 3 | United States | |
| 213 | NCT00625469 | October 2007 | 11 June 2018 | Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan | Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study | Pulmonary Arterial Hypertension;Idiopathic Pulmonary Fibrosis | Drug: bosentan | Rajan Saggar | Actelion | Not recruiting | N/A | N/A | All | 0 | Phase 4 | United States |
| 214 | EUCTR2007-002324-15-GB | 04/09/2007 | 19 March 2012 | The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPAC | The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPAC | Idiopathic Interstitial Pneumonia MedDRA version: 9.1 Level: LLT Classification code 10022619 Term: Interstitial pulmonary fibrosis | Trade Name: Septrin Product Name: co-trimoxazole Product Code: N/A Pharmaceutical Form: Tablet INN or Proposed INN: N/A CAS Number: 8064902 Current Sponsor code: N/A Other descriptive name: CO-TRIMOXAZOLE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 480- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | University of East Anglia | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
| 215 | NCT00532233 | September 2007 | 16 December 2017 | SD, IL-13 Production Rate in IPF | A Open-label, Multicenter Study, With a Single Intravenous Dose of QAX576 to Determine IL-13 Production in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: QAX576 | Novartis Pharmaceuticals | Not recruiting | 40 Years | 80 Years | All | 52 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 216 | NCT00514683 | August 2007 | 19 October 2017 | Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis | A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out. | Pulmonary Fibrosis | Drug: low dose BIBF1120 once daily;Drug: low dose BIBF 1120 twice daily;Drug: intermediate dose BIBF 1120 twice daily;Drug: high dose BIBF 1120 twice daily;Drug: placebo | Boehringer Ingelheim | Not recruiting | 40 Years | N/A | All | 432 | Phase 2 | Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;El Salvador | |
| 217 | NCT00517933 | August 2007 | 19 October 2017 | Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis | Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis;Hypertension, Pulmonary | Drug: Sildenafil Citrate;Other: Placebo | Duke University | National Heart, Lung, and Blood Institute (NHLBI);Pfizer | Not recruiting | 18 Years | N/A | All | 180 | Phase 3 | United States |
| 218 | EUCTR2004-001876-37-DE | 27/07/2007 | 19 March 2012 | BENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis. - BENEFIT | BENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis. - BENEFIT | Idiopathic Pulmonary Fibrosis MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder for solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Academic Medical Centre | Authorised | Female: yes Male: yes | 18 | Germany | ||||
| 219 | EUCTR2006-002875-42-DE | 06/07/2007 | 11 February 2013 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Pharmaceutical Form: Capsule, soft Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Boehringer Ingelheim | Not Recruiting | Female: yes Male: yes | 400 | Portugal;France;Hungary;Greece;Spain;Belgium;Ireland;Bulgaria;Netherlands;Germany;United Kingdom;Italy | ||||
| 220 | JPRN-UMIN000015929 | 2007/05/10 | 2 April 2019 | Prospective observational study of Idiopathic pulmonary fibrosis with Non-small-cell lung cancer(LOGIK0603) | Idiopathic pulmonary fibrosis | Carboplatin/paclitaxel combination therapy (dosage and administration) Paclitaxel (PAC):175-200mg/m2 at day1 and carboplatin (CBDCA): AUC 5-6min.mg/mL at day1 are administered and repeated every 21 days as 1 course and the treatment is aimed for more than 3 courses. *The study is discontinued at that point if it becomes PD. | Lung Oncology Group in Kyushu, Japan (LOGIK) | Not Recruiting | 20years-old | 75years-old | Male and Female | 60 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 221 | EUCTR2006-001183-24-NL | 06/03/2007 | 19 March 2012 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: BOSENTAN CAS Number: 147536978 Current Sponsor code: Ro 47-0203 Other descriptive name: Tracleer Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 62.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: BOSENTAN CAS Number: 147536978 Current Sponsor code: Ro 47-0203 Other descriptive name: Tracleer Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | ACTELION PHARMACEUTICALS LTD | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | |||
| 222 | NCT00391443 | February 2007 | 19 October 2017 | BUILD 3: Bosentan Use in Interstitial Lung Disease | Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study. | Idiopathic Pulmonary Fibrosis | Drug: Bosentan;Drug: Placebo | Actelion | Not recruiting | 18 Years | N/A | All | 616 | Phase 3 | United States;Australia;Austria;Belgium;Canada;Croatia;Czech Republic;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Spain;Switzerland;United Kingdom;Denmark;Former Serbia and Montenegro;Slovakia | |
| 223 | NCT00625079 | February 2007 | 11 June 2018 | Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil | Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study | Pulmonary Arterial Hypertension;Idiopathic Pulmonary Fibrosis;Interstitial Lung Disease;Pulmonary Hypertension | Drug: sildenafil | University of California, Los Angeles | Pfizer | Not recruiting | N/A | N/A | All | 0 | Phase 4 | United States |
| 224 | NCT00563212 | January 2007 | 15 October 2018 | A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis | A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Drug: aerosol interferon-gamma | New York University School of Medicine | National Center for Research Resources (NCRR);Stony Brook University;Philips Respironics | Not recruiting | 40 Years | 75 Years | All | 12 | Phase 1 | United States |
| 225 | EUCTR2006-001183-24-BE | 12/12/2006 | 19 March 2012 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: BOSENTAN CAS Number: 147536978 Current Sponsor code: Ro 47-0203 Other descriptive name: Tracleer Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 62.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: BOSENTAN CAS Number: 147536978 Current Sponsor code: Ro 47-0203 Other descriptive name: Tracleer Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | ACTELION PHARMACEUTICALS LTD | Not Recruiting | Female: yes Male: yes | 460 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 226 | EUCTR2006-002174-22-DE | 08/11/2006 | 19 March 2012 | Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosis | Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosis | Pulmonary Fibrosis categorized as UIP or NSIP | Product Name: Aviptadil, 66 microgram/mL Pharmaceutical Form: Inhalation vapour, solution CAS Number: 40077-57-4 Other descriptive name: Vasoactive intestinal peptide Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 66.6- Pharmaceutical form of the placebo: Inhalation vapour, solution Route of administration of the placebo: Inhalation use | Mondobiotech Laboratories Anstalt | Authorised | Female: yes Male: yes | Germany | |||||
| 227 | NCT00463983 | October 2006 | 19 February 2015 | Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide | Phase 2 Study of Long Acting Octreotide in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: octreotide | Institut National de la Santé Et de la Recherche Médicale, France | Not recruiting | 40 Years | N/A | Both | 25 | Phase 1/Phase 2 | France | |
| 228 | NCT00287716 | July 14, 2006 | 16 December 2017 | Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone;Drug: Placebo | Genentech, Inc. | Not recruiting | 40 Years | 80 Years | All | 435 | Phase 3 | United States | |
| 229 | NCT00359736 | July 2006 | 16 December 2017 | Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis | Vasodilator Therapy and Exercise Tolerance in IPF Patients | Alveolitis, Fibrosing;Fibrosis, Pulmonary;Hypertension, Pulmonary | Drug: sildenafil | VA Office of Research and Development | Not recruiting | 40 Years | 85 Years | All | 29 | Phase 2 | United States | |
| 230 | EUCTR2006-000252-41-GB | 29/06/2006 | 19 March 2012 | A Randomized, Double-Blind, Placebo Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pirfenidone CAS Number: 5317-13-8 Current Sponsor code: PIR, S-7701 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 133- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Pirfenidone Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pirfenidone CAS Number: 5317-13-8 Current Sponsor code: PIR, S-7701 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 267- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | InterMune, Inc. | Authorised | Female: yes Male: yes | 325 | Phase 3 | United Kingdom;Italy | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 231 | NCT00203697 | April 2006 | 19 February 2015 | Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study | Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study | Idiopathic Pulmonary Fibrosis | Drug: minocycline | University of California, Los Angeles | Not recruiting | 20 Years | 79 Years | Both | Phase 3 | United States | ||
| 232 | NCT00287729 | April 2006 | 16 December 2017 | Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone;Drug: Placebo | Genentech, Inc. | Not recruiting | 40 Years | 80 Years | All | 344 | Phase 3 | United States | |
| 233 | NCT00125385 | July 2005 | 20 April 2015 | Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: GC1008 | Genzyme, a Sanofi Company | Not recruiting | 18 Years | 79 Years | Both | 25 | Phase 1 | United States;Belgium | |
| 234 | NCT00518310 | May 2005 | 19 February 2015 | Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis | Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study | Idiopathic Pulmonary Fibrosis | Drug: Placebo;Drug: AZAPRED | Thorax National Institute | Sociedad Chilena de Enfermedades Respiratorias;Servicio de Salud Metropolitano Oriente, Ministerio de Salud de Chile | Recruiting | 45 Years | 79 Years | Both | 100 | N/A | Chile |
| 235 | NCT00109681 | April 2005 | 19 February 2015 | Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Pilot Efficacy of Iloprost Inhalation Solution in Adults With Abnormal Pulmonary Arterial Pressure and Exercise Limitation Associated With Idiopathic Pulmonary Fibrosis (IPF) | Pulmonary Fibrosis;Pulmonary Hypertension | Drug: Iloprost Inhalation Solution (Ventavis) | Actelion | Not recruiting | 40 Years | 85 Years | Both | 50 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 236 | EUCTR2004-000029-31-IE | 28/01/2005 | 19 March 2012 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIRE | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIRE | Idiopathic Pulmonary Fibrosis (IPF) | Trade Name: Immukin Product Name: Interferon gamma-1b Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | InterMune | Authorised | Female: yes Male: yes | 600 | Phase 3 | Ireland | |||
| 237 | EUCTR2004-001261-17-IE | 28/01/2005 | 19 March 2012 | An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis | An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Trade Name: Immukin Product Name: Interferon gamma-1b Pharmaceutical Form: Solution for injection | InterMune | Authorised | Female: yes Male: yes | Ireland | |||||
| 238 | NCT00105183 | January 2005 | 19 October 2017 | EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection | A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s) | Chronic Obstructive Pulmonary;Idiopathic Pulmonary Fibrosis;Cystic Fibrosis;Bronchiectasis;Pulmonary Vascular Disease | Biological: Placebo;Biological: EZ-2053;Biological: EZ-2053 5mg/kg | Neovii Biotech | Not recruiting | 18 Years | N/A | All | 223 | Phase 3 | United States;Australia;Austria;Canada | |
| 239 | NCT00352482 | November 2004 | 8 August 2016 | Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension | Sildenafil Treatment in Patients With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - a Pilot Cross-over Study | Pulmonary Fibrosis;Hypertension, Pulmonary | Drug: Sildenafil (50 mg) | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 19 Years | N/A | Both | 20 | Phase 2 | United States | |
| 240 | NCT00075998 | December 2003 | 19 February 2015 | The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial) | Idiopathic Pulmonary Fibrosis;Lung Disease;Pulmonary Fibrosis | Drug: Interferon gamma-1b (Actimmune) | InterMune | Not recruiting | 40 Years | 79 Years | Both | 826 | Phase 3 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 241 | NCT00076635 | November 2003 | 19 February 2015 | An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF | An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Pulmonary Fibrosis;Lung Disease | Drug: Interferon gamma-1b | InterMune | Not recruiting | N/A | N/A | Both | 91 | Phase 3 | United States | |
| 242 | NCT00162760 | October 2003 | 19 February 2015 | Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide | Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide | Idiopathic Pulmonary Fibrosis (IPF) | Drug: Thalidomide | Johns Hopkins University | Celgene Corporation | Not recruiting | 50 Years | 80 Years | Both | 19 | Phase 2 | United States |
| 243 | NCT00080223 | August 31, 2003 | 16 December 2017 | Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis | An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Pulmonary Fibrosis | Drug: Pirfenidone | Genentech, Inc. | Not recruiting | 40 Years | 85 Years | All | 83 | Phase 2 | United States | |
| 244 | NCT00071461 | August 2003 | 19 February 2015 | Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension | Idiopathic Pulmonary Fibrosis | Drug: bosentan;Drug: Placebo | Actelion | Not recruiting | 18 Years | N/A | Both | 158 | Phase 2/Phase 3 | United States;Canada;France;Germany;Israel;Italy;Switzerland;United Kingdom | |
| 245 | NCT00063869 | July 2003 | 19 February 2015 | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis | A Double-blind, Parallel, Placebo-controlled, Randomized Study of the Efficacy and Safety of Etanercept in Patients With Idiopathic Pulmonary Fibrosis. | Pulmonary Fibrosis | Drug: Etanercept | Wyeth is now a wholly owned subsidiary of Pfizer | Not recruiting | 40 Years | 80 Years | Both | 88 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 246 | NCT00131274 | April 2003 | 19 February 2015 | Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study | A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Lung Disease;Pulmonary Fibrosis | Drug: Imatinib Mesylate (Gleevec) | Daniels, Craig E., M.D. | Novartis | Not recruiting | 20 Years | 79 Years | Both | 120 | Phase 2/Phase 3 | |
| 247 | NCT00189176 | March 2003 | 19 February 2015 | Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis | Phase I/II Trial of Tetrathiomolybdate (TM) in Patients With Usual Interstitial Pneumonia Refractory to Previous Therapy | Idiopathic Pulmonary Fibrosis | Drug: Tetrathiomolybdate | University of Michigan | Coalition for Pulmonary Fibrosis | Not recruiting | 35 Years | 80 Years | Both | 23 | Phase 1/Phase 2 | United States |
| 248 | NCT00052052 | September 2002 | 19 February 2015 | An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) | An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis. | Lung Disease;Pulmonary Fibrosis | Drug: interferon-gamma 1b | InterMune | Not recruiting | 20 Years | 79 Years | Both | 210 | Phase 2 | United States | |
| 249 | NCT00052039 | April 2002 | 19 February 2015 | A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone | A Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving Prednisone | Lung Disease;Pulmonary Fibrosis | Drug: interferon-gamma 1b;Drug: azathioprine | InterMune | Not recruiting | 20 Years | 79 Years | Both | 0 | Phase 3 | Italy | |
| 250 | NCT00047658 | November 2001 | 19 February 2015 | A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon Gamma-1b Administered Subcutaneously to Patients With IPF Followed by an Open-Label Extension | Idiopathic Pulmonary Fibrosis | Drug: Interferon-gamma 1b | InterMune | Not recruiting | 20 Years | 79 Years | Both | 32 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 251 | NCT00262405 | January 2001 | 14 December 2015 | Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis | Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: zileuton;Drug: azathioprine/prednisone | University of Michigan | National Institutes of Health (NIH) | Not recruiting | 35 Years | 80 Years | Both | 44 | Phase 2 | United States |
| 252 | NCT01442779 | September 2000 | 19 October 2017 | Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis | Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis | Respiratory Tract Diseases;Lung Diseases;Lung Diseases, Interstitial;Pulmonary Fibrosis | Drug: Interferon alpha oral lozenge | Texas Tech University Health Sciences Center | Amarillo Biosciences, Inc. | Not recruiting | 50 Years | N/A | All | 18 | Phase 2 | United States |
| 253 | NCT00047645 | April 2000 | 19 February 2015 | A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Interferon-gamma 1b | InterMune | Not recruiting | 20 Years | 79 Years | Both | 330 | Phase 3 | United States | |
| 254 | NCT00639496 | March 2000 | 16 March 2015 | Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) | Pulmonary Fibrosis | Drug: n-acetylcysteine;Drug: placebo | Zambon SpA | Not recruiting | 18 Years | 75 Years | Both | 184 | Phase 3 | Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom | |
| 255 | NCT00074698 | September 1994 | 19 February 2015 | Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis | A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: FG-3019 | FibroGen | Not recruiting | 21 Years | 80 Years | Both | 27 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 256 | NCT03591926 | January 1900 | 15 October 2018 | A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | A Phase 2a, 24-Week, Multi-Center, Open-Label Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: SM04646 | Samumed LLC | Not recruiting | 40 Years | 80 Years | All | 0 | Phase 2 | Australia;New Zealand | |
| 257 | JPRN-JapicCTI-142452 | 23 April 2019 | A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis | A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Intervention name : Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor Dosage And administration of the intervention : Low Dose, Biological: tralokinumab cohort 1, High Dose, Biological: tralokinumab cohort 2 | AstraZeneca | MedImmune LLC | 50 | BOTH | Phase 2 |